[
  {
    "chunk_id": 0,
    "text": "Chronic kidney disease: assessment and management NICE guideline Published: 25 August 2021 Last updated: 24 November 2021 www. nice. org. uk/guidance/ng203 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). Chronic kidney disease: assessment and management (NG203) Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Contents Overview 5 Who is it for? 5 Recommendations 6 1. 1 Investigations for chronic kidney disease 6 1. 2 Classification of chronic kidney disease in adults 13 1. 3 Frequency of monitoring 15 1. 4 Information and education for people with chronic kidney disease 18 1. 5 Risk assessment, referral criteria and shared care 21 1. 6 Pharmacotherapy 23 1. 7 Diagnosing and assessing anaemia 29 1. 8 Managing anaemia 30 1. 9 Assessing and optimising erythropoiesis in people with anaemia 34 1. 10 Monitoring anaemia treatment 43 1. 11 Hyperphosphataemia in people with chronic kidney disease stage 4 or 5 46 1. 12 Other complications in adults 50 Terms used in this guideline 51 Recommendations for research 54 Key recommendations for research 54 Other recommendations for research 56 Rationale and impact 59 Creatinine-based estimate of glomerular filtration rate (glomerular filtration rate) 59 Investigations for proteinuria 60 Reagent strips for proteinuria and haematuria 61 Who should be tested for chronic kidney disease 62 Frequency of monitoring 63 Risk assessment, referral criteria and shared care 64 Pharmacotherapy for blood pressure control 65 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Pharmacotherapy for proteinuria and choice of antihypertensive agent 66 Diagnostic role of glomerular filtration rate 68 Optimal hemoglobin levels 69 Correcting iron deficiency 70 Hyperphosphataemia in people with chronic kidney disease stage 4 or 5 71 Context 74 Finding more information and committee details 76 Update information 77 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) This guideline replaces CG157, CG182, NG8 and ESNM51. This guideline is the basis of QS5 and QS209.",
    "word_count": 589,
    "char_count": 3974,
    "sentence_count": 38,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 0,
      "total_chunks": 36,
      "position": "1/36",
      "section": "Chronic kidney disease:",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "proteinuria",
        "creatinine",
        "hemoglobin",
        "iron",
        "antihypertensive",
        "blood pressure control",
        "monitoring",
        "stage 4"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 1,
    "text": "This guideline is the basis of QS5 and QS209. Overview This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (chronic kidney disease). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with chronic kidney disease. Who is it for? Healthcare professionals Commissioners and providers People with chronic kidney disease, their families and carers NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Recommendations People have the right to be involved in discussions and make informed decisions about their care, as described in NICEs information on making decisions about your care. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding. Adults, children and young people Some recommendations in this guideline apply to adults only, and we have specified adults in these individual recommendations. When a recommendation applies to children and young people only, we have also specified this in the recommendation. When recommendations apply to adults, children and young people we have specified this in recommendations at the beginning of a section. But for brevity, we have used people for later recommendations. When a recommendation refers to people, this means adults, children and young people. 1. 1 Investigations for chronic kidney disease Measuring kidney function Creatinine-based estimate of glomerular filtration rate 1. 1. 1 Whenever a request for serum creatinine measurement is made, clinical laboratories should report an estimate of (eGFRcreatinine) using a prediction equation (see recommendation 1. 1. 2) in addition to reporting the serum creatinine result. eGFRcreatinine may be less reliable in certain situations (for example, acute NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) kidney injury, pregnancy, oedematous states, muscle wasting disorders, and in adults who are malnourished, who have higher muscle mass or use protein supplements, or who have had an amputation) and has not been well validated in certain ethnic groups (for example, black, Asian and other minority ethnic groups with chronic kidney disease living in the UK). 2014 1. 1. 2 Clinical laboratories should: use the Chronic Kidney Disease Epidemiology Collaboration (chronic kidney disease-EPI) creatinine equation to estimate GFRcreatinine for adults, using creatinine assays with calibration traceable to standardised reference material use creatinine assays that are specific (for example, enzymatic assays) and zero-biased compared with isotope dilution mass spectrometry (IDMS) participate in a UK national external quality assessment scheme for creatinine. 2014 The committee reviewed the evidence on creatinine-based estimation of glomerular filtration rate (glomerular filtration rate) in 2021. For a short explanation of why they did not make new recommendations, see the rationale and impact section on creatinine-based estimate of glomerular filtration rate. Full details of the evidence and the committees discussion are in evidence review A: diagnostic accuracy of estimated glomerular filtration rate calculations in adults, children, and young people from black, Asian and other minority ethnic groups with chronic kidney disease. 1. 1. 3 Interpret eGFRcreatinine with caution in adults with extremes of muscle mass, for example, in bodybuilders, people who have had an amputation or people with muscle wasting disorders. (Reduced muscle mass will lead to overestimation and increased muscle mass to underestimation of the glomerular filtration rate. ) 2008 1. 1.",
    "word_count": 589,
    "char_count": 4097,
    "sentence_count": 37,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 1,
      "total_chunks": 36,
      "position": "2/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "creatinine",
        "serum creatinine",
        "supplements",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 2,
    "text": "2008 1. 1. 4 Advise adults not to eat any meat in the 12 hours before having a blood test for eGFRcreatinine. Avoid delaying the despatch of blood samples to ensure that they are received and processed by the laboratory within 12 hours of venepuncture. 2008 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Reporting and interpreting glomerular filtration rate values 1. 1. 5 Clinical laboratories should report estimated glomerular filtration rate either as a whole number if it is 90 ml/ min/1. 73 m2 or less, or as greater than 90 milliliters per minute/1. 73 m2. 2014 1. 1. 6 If estimated glomerular filtration rate is greater than 90 milliliters per minute/1. 73 m2, use an increase in serum creatinine concentration of more than 20% to infer significant reduction in kidney function. 2014 1. 1. 7 Interpret estimated glomerular filtration rate values of 60 milliliters per minute/1. 73 m2 or more with caution, bearing in mind that estimates of glomerular filtration rate become less accurate as the true glomerular filtration rate increases. 2014 1. 1. 8 Confirm an estimated glomerular filtration rate result of less than 60 milliliters per minute/1. 73 m2 in an adult not previously tested by repeating the test within 2 weeks. Allow for biological and analytical variability of serum creatinine (Â±5%) when interpreting changes in estimated glomerular filtration rate. 2008 When highly accurate measures of glomerular filtration rate are needed 1. 1. 9 If a highly accurate measure of glomerular filtration rate is needed, for example, during monitoring of chemotherapy and in the evaluation of kidney function in potential living donors, consider a reference standard measure (inulin, 51Cr-European Dialysis and Transplant Association, 125I-iothalamate or iohexol). 2008 Investigations for proteinuria 1. 1. 10 Do not use reagent strips to identify proteinuria in children and young people. 2021 1. 1. 11 Do not use reagent strips to identify proteinuria in adults unless they are capable of specifically measuring albumin at low concentrations and expressing the result as an albumin: creatinine ratio (albumin-creatinine ratio). 2008 1. 1. 12 For the initial detection of proteinuria in adults, children and young people: use urine albumin-creatinine ratio rather than protein: creatinine ratio (protein-creatinine ratio) because of the greater sensitivity for low levels of proteinuria NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) check an albumin-creatinine ratio between 3 magnesium/mmol and 70 magnesium/mmol in a subsequent early morning sample to confirm the result. A repeat sample is not needed if the initial albumin-creatinine ratio is 70 magnesium/mmol or more. 2021 1. 1. 13 Regard a confirmed albumin-creatinine ratio of 3 magnesium/mmol or more as clinically important proteinuria. 2021 1. 1. 14 Measure proteinuria with urine albumin-creatinine ratio in the following groups: adults, children and young people with diabetes (type 1 or type 2) adults with an estimated glomerular filtration rate of less than 60 milliliters per minute/1. 73 m2 adults with an estimated glomerular filtration rate of 60 milliliters per minute/1. 73 m2 or more if there is a strong suspicion of chronic kidney disease children and young people without diabetes and with creatinine above the upper limit of the age-appropriate reference range. When albumin-creatinine ratio is 70 magnesium/mmol or more, protein-creatinine ratio can be used as an alternative to albumin-creatinine ratio. 2021 For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on investigations for proteinuria.",
    "word_count": 592,
    "char_count": 3888,
    "sentence_count": 51,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 2,
      "total_chunks": 36,
      "position": "3/36",
      "content_type": "monitoring",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "creatinine",
        "magnesium",
        "serum creatinine",
        "dialysis",
        "monitoring",
        "albumin-creatinine ratio"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 3,
    "text": "Full details of the evidence and the committees discussion are in evidence review B: accuracy of albumin: creatinine ratio versus protein: creatinine ratio measurements to quantify proteinuria in children and young people with chronic kidney disease. Incidental finding of proteinuria on reagent strips 1. 1. 15 If unexplained proteinuria is an incidental finding on a reagent strip, offer testing for chronic kidney disease using eGFRcreatinine and albumin-creatinine ratio. 2021 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Haematuria 1. 1. 16 Use reagent strips to test for haematuria in adults, children and young people (see recommendation 1. 1. 14 for people who should be tested for haematuria): Evaluate further for results of 1 or higher. Do not use urine microscopy to confirm a positive result. 2021 For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on reagent strips for proteinuria and haematuria. Full details of the evidence and the committees discussion are in evidence review C: accuracy of reagent strips for detecting protein and blood in urine in children and young people with chronic kidney disease. Managing isolated invisible haematuria 1. 1. 17 When there is the need to differentiate persistent invisible haematuria in the absence of proteinuria from transient haematuria, regard 2 out of 3 positive reagent strip tests as confirmation of persistent invisible haematuria. 2008 1. 1. 18 Persistent invisible haematuria, with or without proteinuria, should prompt investigation for urinary tract malignancy in appropriate age groups (see NICEs guideline on suspected cancer: recognition and referral). 2008 1. 1. 19 Persistent invisible haematuria in the absence of proteinuria should be followed up annually with repeat testing for haematuria (see recommendations 1. 1. 17 and 1. 1. 18), proteinuria or albuminuria, glomerular filtration rate and blood pressure monitoring as long as the haematuria persists. 2008 Who should be tested for chronic kidney disease 1. 1. 20 Monitor glomerular filtration rate at least annually in adults, children and young people who are taking NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) medicines that can adversely affect kidney function, such as calcineurin inhibitors (for example, ciclosporin or tacrolimus), lithium or non-steroidal anti-inflammatory drugs (long-term chronic use of NSAIDs). 2021 1. 1. 21 Offer testing for chronic kidney disease using eGFRcreatinine and albumin-creatinine ratio to adults with any of the following risk factors: diabetes hypertension previous episode of acute kidney injury cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease or cerebral vascular disease) structural renal tract disease, recurrent renal calculi or prostatic hypertrophy multisystem diseases with potential kidney involvement, for example, systemic lupus erythematosus gout family history of end-stage renal disease (glomerular filtration rate category G5) or hereditary kidney disease incidental detection of haematuria or proteinuria. 2021 1. 1. 22 Offer testing for chronic kidney disease using eGFRcreatinine and albumin-creatinine ratio to children and young people with any of the following risk factors: previous episode of acute kidney injury solitary functioning kidney. 2021 1. 1. 23 Consider testing for chronic kidney disease using eGFRcreatinine and albumin-creatinine ratio in children and young people with any of the following risk factors: low birth weight (2, 500 g or lower) diabetes NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights).",
    "word_count": 568,
    "char_count": 3915,
    "sentence_count": 45,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 3,
      "total_chunks": 36,
      "position": "4/36",
      "section": "Full details of the evidence and the committees discussion are in evidence review B:",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "kidney function",
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "cardiovascular disease",
        "heart failure"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 4,
    "text": "All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) hypertension cardiac disease structural renal tract disease or recurrent renal calculi multisystem diseases with potential kidney involvement, for example, systemic lupus erythematosus family history of end-stage renal disease (glomerular filtration rate category G5) or hereditary kidney disease incidental detection of haematuria or proteinuria. 2021 1. 1. 24 Do not use any of the following as risk factors indicating testing for chronic kidney disease in adults, children and young people: age gender ethnicity obesity in the absence of metabolic syndrome, diabetes or hypertension. 2021 1. 1. 25 Monitor adults, children and young people for the development or progression of chronic kidney disease for at least 3 years after acute kidney injury (longer for people with acute kidney injury stage 3) even if estimated glomerular filtration rate has returned to baseline. 2021 1. 1. 26 For guidance on albumin-creatinine ratio monitoring for children and young people with diabetes, see the NICE guideline on diabetes in children: monitoring for complications and associated conditions of type 1 diabetes monitoring for complications and associated conditions of type 2 diabetes. 2021 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on who should be tested for chronic kidney disease. Full details of the evidence and the committees discussion are in evidence review D: children and young people who should be tested for chronic kidney disease. 1. 2 Classification of chronic kidney disease in adults 1. 2. 1 Classify chronic kidney disease in adults using a combination of glomerular filtration rate and albumin-creatinine ratio categories (as described in table 1). Be aware that: increased albumin-creatinine ratio is associated with increased risk of adverse outcomes decreased glomerular filtration rate is associated with increased risk of adverse outcomes increased albumin-creatinine ratio and decreased glomerular filtration rate in combination multiply the risk of adverse outcomes. 2014 1. 2. 2 Do not determine management of chronic kidney disease solely by age. 2014 Table 1 Risk of adverse outcomes in adults by glomerular filtration rate and albumin-creatinine ratio category albumin-creatinine ratio category A1: normal to albumin-creatinine ratio category A2: albumin-creatinine ratio category A3: mildly increased (less than 3 moderately increased severely increased magnesium/mmol) (3 to 30 magnesium/mmol) (over 30 magnesium/mmol) Low risk glomerular filtration rate category G1: normal and high (90 No chronic kidney disease if there are Moderate risk High risk milliliters per minute/1. 73 m2 or over) no other markers of kidney damage Low risk glomerular filtration rate category G2: mild reduction No chronic kidney disease if there are related to normal range for a young Moderate risk High risk adult (60 to 89 milliliters per minute/1. 73 m2) no other markers of kidney damage glomerular filtration rate category G3a: mild to moderate Moderate risk High risk Very high risk reduction (45 to 59 milliliters per minute/1. 73 m2) glomerular filtration rate category G3b: moderate to severe High risk Very high risk Very high risk reduction (30 to 44 milliliters per minute/1. 73 m2) NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights).",
    "word_count": 548,
    "char_count": 3690,
    "sentence_count": 32,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 4,
      "total_chunks": 36,
      "position": "5/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "end-stage renal disease",
        "proteinuria",
        "creatinine",
        "magnesium",
        "monitoring",
        "stage 3",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 5,
    "text": "73 m2) NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) albumin-creatinine ratio category A1: normal to albumin-creatinine ratio category A2: albumin-creatinine ratio category A3: mildly increased (less than 3 moderately increased severely increased magnesium/mmol) (3 to 30 magnesium/mmol) (over 30 magnesium/mmol) glomerular filtration rate category G4: severe reduction (15 Very high risk Very high risk Very high risk to 29 milliliters per minute/1. 73 m2) glomerular filtration rate category G5: kidney failure (under Very high risk Very high risk Very high risk 15 milliliters per minute/1. 73 m2) Adapted with permission from the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Abbreviations: albumin-creatinine ratio, albumin creatinine ratio; chronic kidney disease, chronic kidney disease; glomerular filtration rate, glomerular filtration rate. Investigating the cause of chronic kidney disease and determining the risk of adverse outcomes 1. 2. 3 Agree a plan to establish the cause of chronic kidney disease during an informed discussion with the person with chronic kidney disease, particularly if the cause may be treatable (for example, urinary tract obstruction, medicines that can adversely affect kidney function or glomerular disease). 2014 1. 2. 4 Use the persons glomerular filtration rate and albumin-creatinine ratio categories (see table 1) to indicate their risk of adverse outcomes (for example, chronic kidney disease progression, acute kidney injury, all-cause mortality and cardiovascular events) and discuss this with them. 2014 Indications for renal ultrasound in adults 1. 2. 5 Offer a renal ultrasound scan to all adults with chronic kidney disease who: have accelerated progression of chronic kidney disease (see recommendation 1. 3. 5) have visible or persistent invisible haematuria have symptoms of urinary tract obstruction have a family history of polycystic kidney disease and are older than 20 have a glomerular filtration rate of less than 30 milliliters per minute/1. 73 m2 (glomerular filtration rate category G4 or G5) NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) are considered by a nephrologist to need a renal biopsy. 2008, amended 2014 1. 2. 6 Advise adults with a family history of hereditary kidney disease about the implications of an abnormal result before a renal ultrasound scan is arranged for them. 2008 1. 3 Frequency of monitoring 1. 3. 1 If an adult, child or young person has chronic kidney disease, or is at risk of it, agree the frequency of monitoring (eGFRcreatinine and albumin-creatinine ratio) with them (and their family members or carers, as appropriate), bearing in mind that chronic kidney disease is not progressive in many people. 2021 1. 3. 2 When agreeing the frequency of monitoring, follow: the recommendations on patient views and preferences in NICEs guideline on patient experience in adult NHS services NICEs guideline on shared decision making. 2021 1. 3. 3 See the recommendations on when to refer adults (recommendation 1. 5. 5) and children and young people (recommendation 1. 5. 6) for specialist assessment. 2021 1. 3. 4 Use table 2 to guide the minimum frequency of eGFRcreatinine monitoring, but tailor it according to: the underlying cause of chronic kidney disease the rate of decline in estimated glomerular filtration rate or increase in albumin-creatinine ratio (but be aware that chronic kidney disease progression is often non-linear) other risk factors, including heart failure, diabetes and hypertension changes to their treatment (such as reninangiotensinaldosterone system RAAS antagonists, NSAIDs and diuretics) NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights).",
    "word_count": 594,
    "char_count": 4003,
    "sentence_count": 44,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 5,
      "total_chunks": 36,
      "position": "6/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "creatinine",
        "magnesium",
        "diuretics",
        "heart failure",
        "monitoring"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 6,
    "text": "All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) intercurrent illness (for example acute kidney injury) whether they have chosen conservative management of chronic kidney disease. 2021 Table 2 Minimum number of monitoring checks (eGFRcreatinine) per year for adults, children and young people with or at risk of chronic kidney disease Note: albumin-creatinine ratio monitoring should be individualised based on a persons individual characteristics, risk of progression and whether a change in albumin-creatinine ratio is likely to lead to a change in management. albumin-creatinine ratio category A1: normal to albumin-creatinine ratio category A2: albumin-creatinine ratio category A3: mildly increased (less than moderately increased severely increased 3 magnesium/mmol) (3 to 30 magnesium/mmol) (over 30 magnesium/mmol) glomerular filtration rate category G1: normal and high (90 0 to 1 1 1 or more milliliters per minute/1. 73 m2 or over) glomerular filtration rate category G2: mild reduction related to normal range for a young adult (60 to 0 to 1 1 1 or more 89 milliliters per minute/1. 73 m2) glomerular filtration rate category G3a: mild to moderate 1 1 2 reduction (45 to 59 milliliters per minute/1. 73 m2) glomerular filtration rate category G3b: moderate to severe 1 to 2 2 2 or more reduction (30 to 44 milliliters per minute/1. 73 m2) glomerular filtration rate category G4: severe reduction (15 2 2 3 to 29 milliliters per minute/1. 73 m2) glomerular filtration rate category G5: kidney failure (under 4 4 or more 4 or more 15 milliliters per minute/1. 73 m2) Abbreviations: albumin-creatinine ratio, albumin creatinine ratio; glomerular filtration rate, glomerular filtration rate. For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on frequency of monitoring. Full details of the evidence and the committees discussion are in evidence review E: optimal monitoring frequency and evidence review N: defining clinically significant decline in estimated glomerular filtration rate in terms of risk of kidney disease progression. Defining progression in adults 1. 3. 5 Define accelerated progression of chronic kidney disease in adults as: a sustained decrease in glomerular filtration rate of 25% or more and a change in glomerular filtration rate category NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) within 12 months or a sustained decrease in glomerular filtration rate of 15 milliliters per minute/1. 73 m2 per year. 2014 1. 3. 6 Take the following steps to identify the rate of progression of chronic kidney disease: Obtain a minimum of 3 glomerular filtration rate estimations over a period of not less than 90 days. In adults with a new finding of reduced glomerular filtration rate, repeat the glomerular filtration rate within 2 weeks to exclude causes of acute deterioration of glomerular filtration rate. For example, acute kidney injury or starting reninangiotensin system antagonist therapy. 2008, amended 2014 1. 3. 7 Be aware that adults with chronic kidney disease are at increased risk of progression to end-stage renal disease if they have either of the following: a sustained decrease in glomerular filtration rate of 25% or more over 12 months or a sustained decrease in glomerular filtration rate of 15 milliliters per minute/1. 73 m2 or more over 12 months. 2008, amended 2014 1. 3. 8 When assessing chronic kidney disease progression, extrapolate the current rate of decline of glomerular filtration rate and take this into account when planning intervention strategies, particularly if it suggests that the person might need renal replacement therapy in their lifetime.",
    "word_count": 599,
    "char_count": 3901,
    "sentence_count": 32,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 6,
      "total_chunks": 36,
      "position": "7/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "kidney failure",
        "end-stage renal disease",
        "creatinine",
        "magnesium",
        "monitoring",
        "albumin-creatinine ratio"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 7,
    "text": "2008, amended 2014 Risk factors associated with chronic kidney disease progression in adults 1. 3. 9 Work with adults who have any of the following risk factors for chronic kidney disease progression to optimise their health: cardiovascular disease proteinuria previous episode of acute kidney injury hypertension NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) diabetes smoking African, African-Caribbean or Asian family origin chronic use of NSAIDs untreated urinary outflow tract obstruction. 2014 1. 3. 10 In adults with chronic kidney disease the chronic use of NSAIDs may be associated with progression and acute use is associated with a reversible decrease in glomerular filtration rate. Exercise caution when giving NSAIDs to people with chronic kidney disease over prolonged periods of time. Monitor the effects on glomerular filtration rate, particularly in people with a low baseline glomerular filtration rate and/or in the presence of other risks for progression. 2008 1. 4 Information and education for people with chronic kidney disease 1. 4. 1 Offer people with chronic kidney disease (and their family members or carers, as appropriate) education and information tailored to the severity and cause of chronic kidney disease, the associated complications and the risk of progression. For more guidance, see: the information on enabling patients to actively participate in their care in NICEs guideline on patient experience in adult NHS services NICEs guideline on shared decision making the section on shared decision making in NICEs guideline on babies, children and young peoples experience of healthcare. 2008 1. 4. 2 When developing information or education programmes, involve adults with chronic kidney disease in their development from the outset. The following topics are suggested. What is chronic kidney disease and how does it affect people? What questions should people ask about their kidneys? What treatments are available for chronic kidney disease, what are their advantages and disadvantages, and what complications or side effects may occur as a result NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) of treatment or medication? What can people do to manage and influence their own condition? In what ways could chronic kidney disease and its treatment affect peoples daily life, social activities, work opportunities and financial situation, including benefits and allowances available? How can people cope with and adjust to chronic kidney disease and what sources of psychological support are available? Information about renal replacement therapy (such as the frequency and length of time of dialysis treatment sessions or exchanges and pre-emptive transplantation) and the preparation needed (such as having a fistula or peritoneal catheter), if appropriate for the person. See NICEs guideline on renal replacement therapy and conservative management. Conservative management and when it may be considered. 2008 1. 4. 3 Offer adults with chronic kidney disease (and their family members or carers, as appropriate) highquality information or education programmes as appropriate to the severity of their condition to allow time for them to fully understand and make informed choices about their treatment. 2008 1. 4. 4 Ensure healthcare professionals providing information and education programmes have specialist knowledge about chronic kidney disease and the necessary skills to facilitate learning. 2008 1. 4. 5 Take account of the psychological aspects of coping with chronic kidney disease and offer adults with chronic kidney disease access to support, for example, support groups, counselling or a specialist nurse. 2008 Lifestyle advice 1. 4. 6 Encourage adults with chronic kidney disease to take exercise, achieve a healthy weight and stop smoking. 2008 NICE 2025. All rights reserved.",
    "word_count": 600,
    "char_count": 4041,
    "sentence_count": 46,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 7,
      "total_chunks": 36,
      "position": "8/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "proteinuria",
        "dialysis",
        "fistula",
        "catheter",
        "cardiovascular disease",
        "exercise",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 8,
    "text": "2008 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Dietary interventions 1. 4. 7 Offer dietary advice about potassium, phosphate, calorie and salt intake appropriate to the severity of chronic kidney disease. 2008, amended 2014 1. 4. 8 If dietary intervention is agreed, provide it alongside education, detailed dietary assessment and supervision to ensure malnutrition is prevented. 2008 Low-protein diets 1. 4. 9 Do not offer low-protein diets (dietary protein intake less than 0. 6 to 0. 8 g/kg/ day) to adults with chronic kidney disease. 2014 Self-management 1. 4. 10 Ensure that systems are in place to: inform adults with chronic kidney disease (and their family members or carers, as appropriate) of their diagnosis enable adults with chronic kidney disease (and their family members or carers, as appropriate) to share in decision making about their care support self-management (this includes providing information about blood pressure, smoking cessation, exercise, diet and medicines) and enable adults with chronic kidney disease to make informed choices. 2014 1. 4. 11 Give adults access to their medical data (including diagnosis, comorbidities, test results, treatments and correspondence) through information systems, such as Renal PatientView, to encourage and help them to self-manage their chronic kidney disease. 2014 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 5 Risk assessment, referral criteria and shared care Risk assessment 1. 5. 1 Give adults with chronic kidney disease and their family members or carers (as appropriate) information about their 5-year risk of needing renal replacement therapy (measured using the 4-variable Kidney Failure Risk Equation). Follow NICEs guideline on shared decision making when communicating risk. 2021 1. 5. 2 Use every day, jargon-free language to communicate information on risk. If technical and medical terms are used, explain them clearly. 2021 1. 5. 3 Set aside enough time during the consultation to give information on risk assessment and to answer any questions. Arrange another appointment for more discussion if this is needed. 2021 1. 5. 4 Document the discussion on risk assessment and any decisions the person makes. 2021 Referral criteria 1. 5. 5 Refer adults with chronic kidney disease for specialist assessment (taking into account their wishes and comorbidities) if they have any of the following: a 5-year risk of needing renal replacement therapy of greater than 5% (measured using the 4-variable Kidney Failure Risk Equation) an albumin-creatinine ratio of 70 magnesium/mmol or more, unless known to be caused by diabetes and already appropriately treated (see recommendations 1. 6. 6 to 1. 6. 9) an albumin-creatinine ratio of more than 30 magnesium/mmol (albumin-creatinine ratio category A3), together with haematuria NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) a sustained decrease in estimated glomerular filtration rate of 25% or more and a change in estimated glomerular filtration rate category within 12 months a sustained decrease in estimated glomerular filtration rate of 15 milliliters per minute/1. 73 m2 or more per year hypertension that remains poorly controlled (above the persons individual target) despite the use of at least 4 antihypertensive medicines at therapeutic doses (see also NICEs guideline on hypertension in adults) known or suspected rare or genetic causes of chronic kidney disease suspected renal artery stenosis. 2021 1. 5.",
    "word_count": 564,
    "char_count": 3762,
    "sentence_count": 52,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 8,
      "total_chunks": 36,
      "position": "9/36",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "creatinine",
        "potassium",
        "phosphate",
        "magnesium",
        "diet",
        "dietary protein",
        "malnutrition"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 9,
    "text": "2021 1. 5. 6 Refer children and young people with chronic kidney disease for specialist assessment if they have any of the following: an albumin-creatinine ratio of 3 magnesium/mmol or more, confirmed on a repeat early morning urine sample haematuria any decrease in estimated glomerular filtration rate hypertension known or suspected rare or genetic causes of chronic kidney disease suspected renal artery stenosis renal outflow obstruction. 2021 1. 5. 7 Consider discussing management with a specialist by letter, email, telephone, or virtual meeting, if there are concerns but the person with chronic kidney disease does not need to see a specialist. 2021 1. 5. 8 Refer people with chronic kidney disease and renal outflow obstruction to urological services, unless urgent treatment is needed (for example, for hyperkalaemia, severe uraemia, acidosis or fluid overload). 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Shared care 1. 5. 9 After referral: Agree, document and date a care plan with the person with chronic kidney disease or their family member or carer (as appropriate). Follow: the recommendations on patient views and preferences in NICEs guideline on patient experience in adult NHS services NICEs guideline on shared decision making. Consider routine follow up at the GP surgery or with a paediatrician rather than in a specialist clinic. Specify criteria for future referral and re-referral if GP follow up is agreed. For children and young people, these criteria should be agreed between the GP and secondary care services. 2021 For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on risk assessment, referral criteria and shared care. Full details of the evidence and the committees discussion are in evidence review F: the best combination of measures to identify increased risk of progression in adults, children and young people. 1. 6 Pharmacotherapy Blood pressure control See NICEs guideline on hypertension in adults for advice on blood pressure control in people with frailty and multimorbidity. NICEs guideline on hypertension in adults recommends using clinic blood pressure for monitoring response to lifestyle changes or medical treatment (see recommendation 1. 4. 15). NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 6. 1 In adults with chronic kidney disease and an albumin-creatinine ratio under 70 magnesium/mmol, aim for a clinic systolic blood pressure below 140 mmHg (target range 120 to 139 mmHg) and a clinic diastolic blood pressure below 90 mmHg. 2021 1. 6. 2 In adults with chronic kidney disease and an albumin-creatinine ratio of 70 magnesium/mmol or more, aim for a clinic systolic blood pressure below 130 mmHg (target range 120 to 129 mmHg) and a clinic diastolic blood pressure below 80 mmHg. 2021 1. 6. 3 In children and young people with chronic kidney disease and an albumin-creatinine ratio of 70 magnesium/mol or more, aim for a clinic systolic blood pressure below the 50th percentile for height. 2021 For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on pharmacotherapy for blood pressure control. Full details of the evidence and the committees discussion are in evidence review G: optimal blood pressure targets. Treating hypertension 1. 6. 4 Follow the recommendations on treating hypertension in NICEs guideline on hypertension for adults with chronic kidney disease, hypertension and an albumin-creatinine ratio of 30 magnesium/mmol or less (albumin-creatinine ratio categories A1 and A2). 2014, amended 2021 1. 6.",
    "word_count": 599,
    "char_count": 3869,
    "sentence_count": 45,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 9,
      "total_chunks": 36,
      "position": "10/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "creatinine",
        "magnesium",
        "acidosis",
        "fluid overload",
        "blood pressure control",
        "follow up",
        "monitoring",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 10,
    "text": "2014, amended 2021 1. 6. 5 Offer an angiotensin-receptor blocker (angiotensin receptor blocker) or an angiotensin-converting enzyme (ACE) inhibitor (titrated to the highest licensed dose that the person can tolerate) to adults, children and young people with chronic kidney disease who have hypertension and an albumin-creatinine ratio over 30 magnesium/mmol (albumin-creatinine ratio category A3 or above). 2021 Treating chronic kidney disease in adults, children, and young people with related persistent proteinuria See also: NICEs guideline on type 1 diabetes in adults NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) NICEs guideline on type 2 diabetes in adults NICEs guideline on type 1 and type 2 diabetes in children and young people. Adults 1. 6. 6 For adults with chronic kidney disease and diabetes (type 1 or type 2) offer an angiotensin receptor blocker or an ACE inhibitor (titrated to the highest licensed dose that the person can tolerate) if albumin-creatinine ratio is 3 magnesium/mmol or more. 2021 1. 6. 7 For adults with chronic kidney disease but without diabetes: refer for nephrology assessment and offer an angiotensin receptor blocker or an ACE inhibitor (titrated to the highest licensed dose that they can tolerate), if albumin-creatinine ratio is 70 magnesium/ mmol or more monitor in line with recommendations 1. 3. 1 and 1. 3. 4 if albumin-creatinine ratio is above 30 but below 70 magnesium/mmol; consider discussing with a nephrologist if estimated glomerular filtration rate declines or albumin-creatinine ratio increases. 2021 1. 6. 8 For SGLT2 inhibitors recommended as options in NICE technology appraisal guidance as an add-on to optimised standard care for some adults with chronic kidney disease, see the guidance on: dapagliflozin (TA1075, 2025) empagliflozin (TA942, 2023). 1. 6. 9 Finerenone is recommended as an option in NICE technology appraisal guidance as an add-on to optimised standard care for some adults with stage 3 and 4 chronic kidney disease (with albumin-creatinine ratio 3 magnesium/mmol or more) associated with type 2 diabetes. For full details, see the guidance on finerenone (TA877, 2023). Children and young people 1. 6. 10 For children and young people with chronic kidney disease and diabetes (type 1 or 2), offer an angiotensin receptor blocker or an ACE inhibitor (titrated to the highest licensed dose that they can tolerate) if albumin-creatinine ratio is 3 magnesium/mmol or more. 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 6. 11 For children and young people with chronic kidney disease but without diabetes: offer an angiotensin receptor blocker or an ACE inhibitor if albumin-creatinine ratio (titrated to the highest licensed dose that they can tolerate) is 70 magnesium/mol or more monitor in line with recommendations 1. 3. 1 and 1. 3. 4 if albumin-creatinine ratio is above 30 but below 70 magnesium/mmol; consider discussing with a nephrologist if estimated glomerular filtration rate declines or albumin-creatinine ratio increases. 2021 Medicines optimisation 1. 6. 12 When offering medicines to lower proteinuria to people with frailty or comorbidities, or who are taking many other prescribed medicines, follow the recommendations in NICEs guideline on medicines optimisation to ensure the best possible outcomes. Seek specialist advice if needed, for example from a consultant in care of the elderly, or from a kidney physician if the person asks about contraception. 2021 For a short explanation of why the committee made the 2021 recommendations and how they might affect practice, see the rationale and impact section on pharmacotherapy for proteinuria and choice of antihypertensive agent.",
    "word_count": 594,
    "char_count": 3881,
    "sentence_count": 42,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 10,
      "total_chunks": 36,
      "position": "11/36",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "proteinuria",
        "creatinine",
        "magnesium",
        "antihypertensive",
        "stage 3",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 11,
    "text": "Full details of the evidence and the committees discussion are in evidence review H: interventions to lower proteinuria. Reninangiotensin system antagonists for adults 1. 6. 13 Do not offer a combination of reninangiotensin system antagonists to adults with chronic kidney disease. 2014 1. 6. 14 Explain to adults with chronic kidney disease (and their family members or carers, as appropriate) who are prescribed reninangiotensin system antagonists about the importance of: achieving the optimal tolerated dose of reninangiotensin system antagonists and NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) monitoring estimated glomerular filtration rate and serum potassium in achieving this safely. 2008 1. 6. 15 Measure serum potassium concentrations and estimate the glomerular filtration rate before starting reninangiotensin system antagonists in adults with chronic kidney disease. Repeat these measurements between 1 and 2 weeks after starting reninangiotensin system antagonists and after each dose increase. 2008 1. 6. 16 Do not routinely offer a reninangiotensin system antagonist to adults with chronic kidney disease if their pretreatment serum potassium concentration is greater than 5. 0 mmol/litre. 2008, amended 2014 1. 6. 17 If an adult cannot use reninangiotensin system antagonists because of hyperkalaemia: assess for and treat any other factors that promote hyperkalaemia and recheck serum potassium concentration. 2008 1. 6. 18 Be aware that more frequent monitoring of serum potassium concentration may be needed if medicines known to promote hyperkalaemia are prescribed alongside reninangiotensin system antagonists. 2008 1. 6. 19 Stop reninangiotensin system antagonists in adults if the serum potassium concentration increases to 6. 0 mmol/litre or more and other medicines known to promote hyperkalaemia have been discontinued. 2008 1. 6. 20 For medicines recommended as options in NICE technology appraisal guidance for treating persistent hyperkalaemia in some adults with categories G3b to G5 chronic kidney disease, see the guidance on: sodium zirconium cyclosilicate (TA599, 2022) patiromer (TA623, 2020). 1. 6. 21 After introducing or increasing the dose of reninangiotensin system antagonists in adults, do not modify the dose if either: the glomerular filtration rate decrease from pretreatment baseline is less than 25% or NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) the serum creatinine increase from baseline is less than 30%. 2008 1. 6. 22 If there is a decrease in estimated glomerular filtration rate or increase in serum creatinine after starting or increasing the dose of reninangiotensin system antagonists, but it is less than 25% (estimated glomerular filtration rate) or 30% (serum creatinine) of baseline, repeat the test in 1 to 2 weeks. Do not modify the reninangiotensin system antagonist dose if the change in estimated glomerular filtration rate is less than 25% or the change in serum creatinine is less than 30%. 2008 1. 6. 23 If an adults estimated glomerular filtration rate change is 25% or more, or the change in serum creatinine is 30% or more: investigate other causes of a deterioration in kidney function, such as volume depletion or concurrent medication (for example, NSAIDs) if no other cause for the deterioration in kidney function is found, stop the reninangiotensin system antagonist or reduce the dose to a previously tolerated lower dose, and add an alternative antihypertensive medication if needed. 2008 Statins for adults 1. 6. 24 Follow the recommendations in NICEs guideline on cardiovascular disease: risk assessment and reduction, including lipid modification for the use of statins in adults with chronic kidney disease. 2014 Oral antiplatelets and anticoagulants for adults 1. 6.",
    "word_count": 590,
    "char_count": 3962,
    "sentence_count": 49,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 11,
      "total_chunks": 36,
      "position": "12/36",
      "section": "Full details of the evidence and the committees discussion are in evidence review H:",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "creatinine",
        "sodium",
        "potassium",
        "serum creatinine",
        "antihypertensive",
        "statins"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 12,
    "text": "2014 Oral antiplatelets and anticoagulants for adults 1. 6. 25 Offer antiplatelet medicines to adults with chronic kidney disease for the secondary prevention of cardiovascular disease, but be aware of the increased risk of bleeding. 2014 1. 6. 26 For guidance on oral anticoagulants for people with chronic kidney disease, see NICEs guidelines on atrial fibrillation and venous thromboembolic diseases. 2014, amended 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 7 Diagnosing and assessing anaemia Diagnostic role of haemoglobin levels 1. 7. 1 Consider investigating and managing anaemia in adults, children and young people with chronic kidney disease if: their haemoglobin (hemoglobin) level falls to 110 g/litre or less (or 105 g/litre or less if younger than 2 years) or they develop symptoms attributable to anaemia (such as tiredness, shortness of breath, lethargy and palpitations). 2011 Diagnostic role of glomerular filtration rate 1. 7. 2 In adults, children and young people with anaemia (see recommendation 1. 7. 3): If estimated glomerular filtration rate is above 60 milliliters per minute/1. 73 m2, investigate other causes of anaemia as it is unlikely to be caused by chronic kidney disease. If estimated glomerular filtration rate is between 30 and 60 milliliters per minute/1. 73 m2: investigate other causes of anaemia, but use clinical judgement to decide how extensive this investigation should be, because the anaemia may be caused by chronic kidney disease. If estimated glomerular filtration rate is below 30 milliliters per minute/1. 73 m2, think about other causes of anaemia but note that anaemia is often caused by chronic kidney disease. 2021 For a short explanation of why the committee made the 2021 recommendation and how it might affect practice, see the rationale and impact section on diagnostic role of glomerular filtration rate. Full details of the evidence and the committees discussion are in evidence review I: estimated glomerular filtration rate threshold for the investigation of anaemia due to chronic kidney disease. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Diagnostic tests to determine iron status and predict response to iron therapy 1. 7. 3 Carry out testing to diagnose iron deficiency and determine potential responsiveness to iron therapy and long-term iron requirements every 3 months (every 1 to 3 months for people having haemodialysis). Use percentage of hypochromic red blood cells (% HRC; more than 6%), but only if processing of blood sample is possible within 6 hours. If using percentage of hypochromic red blood cells is not possible, use reticulocyte hemoglobin content (CHr; less than 29 pg) or equivalent tests for example, reticulocyte hemoglobin equivalent. If these tests are not available or the person has thalassaemia or thalassaemia trait, use a combination of transferrin saturation (less than 20%) and serum ferritin measurement (less than 100 micrograms/litre). 2015 1. 7. 4 Do not request transferrin saturation or serum ferritin measurement alone to assess iron deficiency status in people with anaemia of chronic kidney disease. 2015 1. 7. 5 Do not routinely measure erythropoietin levels for the diagnosis or management of anaemia in people with anaemia of chronic kidney disease. 2006 1. 8 Managing anaemia Starting erythropoietic stimulating agent therapy in iron deficiency 1. 8. 1 erythropoiesis-stimulating agent (erythropoietic stimulating agent) therapy should not be started in the presence of absolute iron deficiency without also managing the iron deficiency. 2006 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights).",
    "word_count": 585,
    "char_count": 3844,
    "sentence_count": 47,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 12,
      "total_chunks": 36,
      "position": "13/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "hemoglobin",
        "iron",
        "ferritin",
        "transferrin saturation",
        "erythropoietin",
        "cardiovascular disease"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 13,
    "text": "2006 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Maximum iron levels in people with anaemia of chronic kidney disease 1. 8. 2 In adults, children and young people treated with iron, serum ferritin levels should not rise above 800 micrograms/litre. In order to prevent this, review the dose of iron when serum ferritin levels reach 500 micrograms/litre. 2006 Clinical utility of erythropoiesis-stimulating agent therapy in people with sufficient iron 1. 8. 3 Discuss the pros and cons of a trial of anaemia management with the person with anaemia of chronic kidney disease, and their families and carers if agreed. 2006 1. 8. 4 ESAs need not be administered if the presence of comorbidities, or the prognosis, is likely to negate the benefits of correcting the anaemia. 2006 1. 8. 5 Start a trial of anaemia correction when there is uncertainty over whether the presence of comorbidities, or the prognosis, would negate benefit from correcting the anaemia with ESAs. 2006 1. 8. 6 If a trial of erythropoiesis-stimulating agent therapy is carried out, assess the effectiveness of the trial after an agreed interval. Agree with the person with anaemia of chronic kidney disease (and their families and carers, if appropriate) whether or not to continue erythropoiesis-stimulating agent therapy. 2006 1. 8. 7 Review treatment in all people started on erythropoiesis-stimulating agent therapy after an agreed interval to decide whether or not to continue using ESAs. 2006 Hypoxia-inducible factor prolyl-hydroxylase inhibitors 1. 8. 8 Roxadustat is recommended as an option in NICE technology appraisal guidance for treating symptomatic anaemia in adults with stage 3 to 5 chronic kidney disease and no iron deficiency who are not on dialysis. For full details, see the guidance on roxadustat (TA807, 2022). 1. 8. 9 Vadadustat is recommended as an option in NICE technology appraisal guidance for treating symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. For full details, see the guidance on vadadustat (TA1035, 2025). NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Nutritional supplements 1. 8. 10 Do not prescribe supplements of vitamin C, folic acid or carnitine as adjuvants specifically for the treatment of anaemia of chronic kidney disease. 2006 Androgens 1. 8. 11 Do not use androgens to treat anaemia in people with anaemia of chronic kidney disease. 2006 Secondary hyperparathyroidism 1. 8. 12 Treat clinically relevant secondary hyperparathyroidism in adults, children and young people with chronic kidney disease to improve the management of the anaemia. 2006 1. 8. 13 Cinacalcet is recommended as an option in NICE technology appraisal guidance for treating refractory secondary hyperparathyroidism in some people with endstage renal disease on maintenance dialysis. For full details, see the guidance on cinacalcet (TA117, 2007). 1. 8. 14 Etelcalcetide is recommended as an option in NICE technology appraisal guidance for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis if treatment with a calcimimetic is indicated but cinacalcet is not suitable. For full details, see the guidance on etelcalcetide (TA448, 2017). Person-centred care and ESAs 1. 8. 15 Give adults, children and young people offered erythropoiesis-stimulating agent therapy and their GPs information about why erythropoiesis-stimulating agent therapy is needed, how it works and what benefits and side effects may be experienced. 2006 1. 8. 16 When managing the treatment of anaemia of chronic kidney disease, there should be agreed protocols defining roles and responsibilities of healthcare professionals in primary and secondary care. 2006 NICE 2025. All rights reserved.",
    "word_count": 598,
    "char_count": 3946,
    "sentence_count": 59,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 13,
      "total_chunks": 36,
      "position": "14/36",
      "content_type": "dietary",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "iron",
        "ferritin",
        "supplements",
        "dialysis",
        "stage 3"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 14,
    "text": "2006 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 8. 17 Explain to people receiving erythropoiesis-stimulating agent therapy about the importance of concordance with therapy and the consequences of poor adherence. 2006 1. 8. 18 When prescribing erythropoiesis-stimulating agent therapy, take into account the persons preferences about supervisedor self-administration, dose frequency, pain on injection, method of supplying erythropoiesis-stimulating agent and storage. 2006 1. 8. 19 In order for people to self-administer their erythropoiesis-stimulating agent in a way that is clinically effective and safe, make arrangements to provide ready, reasonable and uninterrupted access to supplies. 2006 Patient education programmes 1. 8. 20 Offer culturally and age-appropriate patient education programmes to all adults, children and young people diagnosed with anaemia of chronic kidney disease (and their families and carers). These should be repeated as requested, and according to the persons changing circumstances. They should include the following key areas: Practical information about how anaemia of chronic kidney disease is managed. Knowledge (for example, about symptoms, iron management, causes of anaemia, associated medications, phases of treatment). Professional support (for example, contact information, community services, continuity of care, monitoring, feedback on progress of results). Lifestyle (for example, diet, physical exercise, maintaining normality, meeting other people with the condition). Adaptation to chronic disease (for example, previous information and expectations, resolution of symptoms). 2006 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 9 Assessing and optimising erythropoiesis in people with anaemia Benefits of treatment with ESAs 1. 9. 1 Offer treatment with ESAs to adults, children and young people with anaemia of chronic kidney disease who are likely to benefit in terms of quality of life and physical function. 2006 Blood transfusions 1. 9. 2 Avoid blood transfusions if possible in people with anaemia of chronic kidney disease in whom kidney transplant is a treatment option. 2006 1. 9. 3 If a transfusion is indicated clinically in a person with anaemia of chronic kidney disease, follow NICEs guideline on blood transfusion. 2006, amended 2015 Comparisons of ESAs 1. 9. 4 Discuss the choice of erythropoiesis-stimulating agent with the person with anaemia of chronic kidney disease when starting treatment and at subsequent review, taking into account: the persons dialysis status the route of administration the local availability of ESAs the lack of evidence comparing the efficacy of ESAs. 2006 Coordinating care 1. 9. 5 Ensure people with anaemia of chronic kidney disease have access to a designated contact person or people who have principal responsibility for their anaemia management and NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) who have skills in the following activities: Monitoring and managing a caseload in line with locally agreed protocols. Providing information, education and support to empower people and their families and carers to participate in their care. Coordinating an anaemia service for people with chronic kidney disease, working between secondary and primary care and providing a single point of contact, to ensure people receive a seamless service of the highest standard. Prescribing medicines related to anaemia management and monitoring their effectiveness. 2006 Providing ESAs 1. 9. 6 Agree a treatment plan between the prescriber and the person with anaemia of chronic kidney disease that ensures erythropoiesis-stimulating agent therapy is clinically effective, consistent and safe.",
    "word_count": 572,
    "char_count": 3982,
    "sentence_count": 49,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 14,
      "total_chunks": 36,
      "position": "15/36",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "iron",
        "diet",
        "dialysis",
        "kidney transplant",
        "exercise",
        "patient education",
        "adherence",
        "quality of life",
        "monitoring"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 15,
    "text": "The plan should be person-centred and include: continuity of medicine supply flexibility of where the medicine is delivered and administered the persons lifestyle and preferences cost of medicine supply desire for self-care if appropriate regular review of the plan in light of changing needs. 2006 ESAs: optimal route of administration 1. 9. 7 Agree the route of administration of ESAs between the person with anaemia of chronic kidney disease and the prescriber, and revise as appropriate. Take into account the following factors: patient population (for example, people having haemodialysis) NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) pain of injection frequency of administration the persons lifestyle and preferences efficacy (for example, subcutaneous compared with intravenous administration, or long-acting compared with short-acting preparations) cost of medicine supply. 2006 1. 9. 8 The prescriber should take into account that when using short-acting ESAs, subcutaneous injection allows the use of lower doses of medicines than intravenous administration. 2006 ESAs: dose and frequency 1. 9. 9 When correcting anaemia of chronic kidney disease, the dose and frequency of erythropoiesis-stimulating agent should be: determined by the duration of action and route of administration of the erythropoiesis-stimulating agent adjusted to keep the rate of hemoglobin increase between 10 and 20 g/litre/month. 2006 Optimal hemoglobin levels 1. 9. 10 When determining individual aspirational hemoglobin ranges for people with anaemia of chronic kidney disease, take into account: their preferences symptoms and comorbidities the necessary treatment. 2011 1. 9. 11 Do not routinely correct hemoglobin to normal levels with ESAs in adults, children and young people with anaemia of chronic kidney disease. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Typically maintain the aspirational hemoglobin range between 100 and 120 g/litre for adults, young people and children aged 2 years and over, and between 95 and 115 g/litre for children under 2 years, reflecting the lower normal range in that age group. To keep the hemoglobin level within the aspirational range, do not wait until hemoglobin levels are outside the aspirational range before adjusting treatment (for example, take action when hemoglobin levels are within 5 g/litre of the ranges limits). Follow the MHRA safety advice on recombinant human erythropoietins, particularly the advice to avoid hemoglobin levels above 120 g/litre because of the increased risk of death and serious adverse cardiovascular events in people with chronic kidney disease. People should have close monitoring to ensure that the lowest approved dose of erythropoiesis-stimulating agent is used to provide adequate control of the anaemia symptoms. 2021 For a short explanation of why the committee made the 2021 recommendation and how it might affect practice, see the rationale and impact section on optimal hemoglobin levels. Full details of the evidence and the committees discussion are in evidence review J: aspirational haemoglobin target range for children and young people with chronic kidney disease. 1. 9. 12 Consider accepting hemoglobin levels below the agreed aspirational range if: high doses of ESAs are needed to achieve the aspirational range or the aspirational range is not achieved despite escalating erythropoiesis-stimulating agent doses. High doses are more than 175 international unit/kg per week for people having haemodialysis; more than 125 international unit/kg per week for people having peritoneal dialysis; more than 100 international unit/kg per week for people not having dialysis. 2011 1. 9. 13 Do not use age alone to determine treatment of anaemia of chronic kidney disease. 2006 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights).",
    "word_count": 597,
    "char_count": 4034,
    "sentence_count": 39,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 15,
      "total_chunks": 36,
      "position": "16/36",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "hemoglobin",
        "dialysis",
        "peritoneal dialysis",
        "monitoring"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 16,
    "text": "2006 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Adjusting erythropoiesis-stimulating agent treatment 1. 9. 14 Optimise iron status before or at the same time as starting ESAs and during maintenance treatment with ESAs. 2006, amended 2011 1. 9. 15 Use of ACE inhibitors or angiotensin type II receptor antagonists is not precluded, but if they are used, an increase in erythropoiesis-stimulating agent therapy should be considered. 2006 1. 9. 16 Take into account hemoglobin measurements when determining the dose and frequency of erythropoiesis-stimulating agent administration. Investigate the cause of an unexpected change in hemoglobin level (that is, intercurrent illness or bleeding) to enable intervention and optimise iron status. Increase or decrease erythropoiesis-stimulating agent dose and/or frequency when hemoglobin measurements fall outside action thresholds (usually below 105 g/litre or above 115 g/litre), or for example when the rate of change of hemoglobin suggests an established trend (for example, greater than 10 g/litre/month). 2006, amended 2011 Correcting iron deficiency 1. 9. 17 Offer iron therapy to adults, children and young people with anaemia of chronic kidney disease who are receiving ESAs to achieve: percentage of hypochromic red blood cells less than 6% (unless ferritin is greater than 800 micrograms/litre) reticulocyte hemoglobin count or equivalent tests above 29 pg (unless serum ferritin is greater than 800 micrograms/litre). If these tests are not available or the person has thalassaemia or thalassaemia trait, iron therapy should maintain transferrin saturation greater than 20% and serum ferritin level greater than 100 micrograms/litre (unless serum ferritin is greater than 800 micrograms/litre). Most adults will need 500 to 1, 000 magnesium of iron (equivalent doses for children) in a single or divided dose depending on the preparation. Intravenous iron NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) should be administered in a setting with facilities for resuscitation. 2015 In August 2021, this was an off-label use of intravenous iron products for some ages of children and young people. See NICEs information on prescribing medicines. 1. 9. 18 Offer a high-dose intravenous iron regimen to adults, children and young people with stage 5 chronic kidney disease on in-centre (hospital or satellite unit) haemodialysis, if they have iron deficiency (see recommendation 1. 7. 3). See table 3 for an example of a high-dose intravenous iron regimen for adults or use a bioequivalent dose of iron. For children and young people, use the maximum dosing regimen in the British National Formulary for Children (BNFc) unless serum ferritin is greater than 800 micrograms/litre when the dose should be withheld. In August 2021, this was an off-label use of intravenous iron products for some children and young people. See NICEs information on prescribing medicines. 2021 Table 3 Example of high-dose intravenous iron regimen for adults Intravenous iron sucrose Iron status (high-dose regimen) 600 magnesium divided equally over 3 First month haemodialysis sessions 200 magnesium during each Second month onwards if ferritin 700 micrograms/litre or less of the first 2 dialysis sessions Second month onwards if ferritin over 700 micrograms/litre and/or transferrin saturation 40% or more and/or C-reactive Withhold iron dose protein (CRP) over 50 magnesium/litre Intravenous iron sucrose based on the high-dose iron regimen in the PIVOTAL trial (Macdougall 2019), which included people with serum ferritin below 400 micrograms/litre, a transferrin saturation below 30% and a CRP below 50 magnesium/litre and on erythropoiesis-stimulating agent. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights).",
    "word_count": 586,
    "char_count": 3971,
    "sentence_count": 38,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 16,
      "total_chunks": 36,
      "position": "17/36",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "magnesium",
        "hemoglobin",
        "iron",
        "ferritin",
        "transferrin saturation",
        "ACE inhibitors",
        "dialysis",
        "stage 5"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 17,
    "text": "NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) For a short explanation of why the committee made the 2021 recommendation and how it might affect practice, see the rationale and impact section on correcting iron deficiency. Full details of the evidence and the committees discussion are in evidence review potassium: anaemia IV iron. Maintaining iron levels after a deficiency is corrected 1. 9. 19 Once the percentage of hypochromic red blood cells is less than 6%, reticulocyte hemoglobin count or equivalent tests are above 29 pg, or transferrin saturation is greater than 20% and serum ferritin level is greater than 100 micrograms/litre, offer maintenance iron to people with anaemia of chronic kidney disease who are receiving ESAs. The dosing regimen will depend on modality, for example people having haemodialysis will need the equivalent of 50 to 60 magnesium intravenous iron per week (or an equivalent dose in children of 1 magnesium/kg/week). 2015 In August 2021, this was an off-label use of intravenous iron products for some ages of children and young people. See NICEs information on prescribing medicines. Monitoring iron status during erythropoiesis-stimulating agent treatment 1. 9. 20 Offer iron therapy to adults, children and young people receiving erythropoiesis-stimulating agent maintenance therapy to keep their: percentage of hypochromic red blood cells less than 6% (unless serum ferritin is greater than 800 micrograms/litre) reticulocyte hemoglobin count or equivalent tests above 29 pg (unless serum ferritin is greater than 800 micrograms/litre) transferrin saturation level above 20% and serum ferritin level above 100 micrograms/litre (unless serum ferritin is greater than 800 micrograms/ NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) litre). The marker of iron status should be monitored every 1 to 3 months in people having haemodialysis. In people who are pre-dialysis or receiving peritoneal dialysis, levels are typically monitored every 3 months. If these people have a normal full blood count there is little benefit in checking iron status. 2015 In August 2021, this was an off-label use of intravenous iron products for some ages of children and young people. See NICEs information on prescribing medicines. Iron therapy for people who are iron deficient and not on erythropoiesis-stimulating agent therapy 1. 9. 21 Offer iron therapy to adults, children and young people with anaemia of chronic kidney disease who are iron deficient and who are not receiving erythropoiesis-stimulating agent therapy, before discussing erythropoiesis-stimulating agent therapy. (In August 2021, this was an off-label use of intravenous iron products for some ages of children and young people. See NICEs information on prescribing medicines). Discuss the risks and benefits of treatment options. Take into account the persons choice. For people who are not having haemodialysis, consider a trial of oral iron before offering intravenous iron therapy. If they are intolerant of oral iron or target hemoglobin levels are not reached within 3 months (see recommendation 1. 9. 11), offer intravenous iron therapy. For people who are having haemodialysis, offer intravenous iron therapy. Offer oral iron therapy to people who are having haemodialysis only if: intravenous iron therapy is contraindicated or the person chooses not to have intravenous iron therapy after discussing the relative efficacy and side effects of oral and intravenous iron therapy. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) 2015 1. 9.",
    "word_count": 576,
    "char_count": 3837,
    "sentence_count": 40,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 17,
      "total_chunks": 36,
      "position": "18/36",
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "magnesium",
        "hemoglobin",
        "iron",
        "ferritin",
        "transferrin saturation",
        "dialysis",
        "peritoneal dialysis",
        "monitoring"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 18,
    "text": "Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) 2015 1. 9. 22 Discuss the results of the iron therapy with the person or, if appropriate, with their family or carers and offer erythropoiesis-stimulating agent therapy if needed (see recommendation 1. 9. 1). 2015 Iron therapy for people who are iron deficient and receiving erythropoiesis-stimulating agent therapy 1. 9. 23 Offer iron therapy to adults, children and young people with anaemia of chronic kidney disease who are iron deficient and who are receiving erythropoiesis-stimulating agent therapy. (In August 2021, this was an off-label use of intravenous iron products for some ages of children and young people. See NICEs information on prescribing medicines). Discuss the risks and benefits of treatment options. Take into account the persons choice. For adults and young people, offer intravenous iron therapy. For children who are having haemodialysis, offer intravenous iron therapy. For children who are not having haemodialysis, consider oral iron. If the child is intolerant of oral iron or target hemoglobin levels are not reached within 3 months (see recommendation 1. 9. 11), offer intravenous iron therapy. 2015 1. 9. 24 Offer oral iron therapy to adults and young people who are receiving erythropoiesis-stimulating agent therapy only if: intravenous iron therapy is contraindicated or the person chooses not to have intravenous iron therapy after discussing the relative efficacy and side effects of oral and intravenous iron therapy. 2015 1. 9. 25 When offering intravenous iron therapy to people not having haemodialysis, consider high-dose low-frequency intravenous iron as the treatment of choice for adults and young people when trying to achieve iron repletion. Take into account all of the following: NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) preferences of the person with anaemia of chronic kidney disease or, if appropriate, their family or carers nursing and administration costs cost of local medicine supply provision of resuscitation facilities. High-dose and low-frequency iron is a maximum of 2 infusions, with a minimum of 500 magnesium of iron in each infusion for adults. Low dose and high frequency is more than 2 infusions with 100 magnesium to 200 magnesium of iron in each infusion for adults. 2015 In August 2021, this was an off-label use of intravenous iron products for some ages of children and young people. See NICEs information on prescribing medicines. 1. 10 Monitoring anaemia treatment Monitoring iron status 1. 10. 1 Do not check iron levels earlier than 1 week after administering intravenous iron in adults, children and young people with anaemia of chronic kidney disease. The length of time to monitoring of iron status is dependent on the product used and the amount of iron given. 2006 1. 10. 2 Carry out routine monitoring of iron stores to prevent iron overload using serum ferritin at intervals of 1 to 3 months. 2006, amended 2015 Monitoring hemoglobin levels 1. 10. 3 In adults, children and young people with anaemia of chronic kidney disease, monitor hemoglobin: every 2 to 4 weeks in the induction phase of erythropoiesis-stimulating agent therapy NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) every 1 to 3 months in the maintenance phase of erythropoiesis-stimulating agent therapy more frequently after an erythropoiesis-stimulating agent dose adjustment in a clinical setting chosen in discussion with the person, taking into account their convenience and local healthcare systems. 2006 Detecting erythropoiesis-stimulating agent resistance 1. 10.",
    "word_count": 588,
    "char_count": 3843,
    "sentence_count": 49,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 18,
      "total_chunks": 36,
      "position": "19/36",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "magnesium",
        "hemoglobin",
        "iron",
        "ferritin",
        "monitoring"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 19,
    "text": "2006 Detecting erythropoiesis-stimulating agent resistance 1. 10. 4 After other causes of anaemia, such as intercurrent illness or chronic blood loss have been excluded, regard people with anaemia of chronic kidney disease as resistant to ESAs when: an aspirational hemoglobin range is not achieved despite treatment with 300 international unit/kg/ week or more of subcutaneous epoetin or 450 international unit/kg/week or more of intravenous epoetin or 1. 5 micrograms/kg/week of darbepoetin or there is a continued need for the administration of high doses of ESAs to maintain the aspirational hemoglobin range. 2006 1. 10. 5 In people with chronic kidney disease, pure red cell aplasia (PRCA) is indicated by a low reticulocyte count, together with anaemia and the presence of neutralising antibodies. Confirm PRCA by the presence of anti-erythropoietin antibodies together with a lack of pro-erythroid progenitor cells in the bone marrow. 2006 1. 10. 6 In people with anaemia of chronic kidney disease, aluminium toxicity should be considered as a potential cause of a reduced response to ESAs after other causes, such as intercurrent illness and chronic blood loss, have been excluded. 2006 Managing erythropoiesis-stimulating agent resistance 1. 10. 7 If aluminium toxicity is suspected in an adult, child or young person with anaemia of chronic kidney disease having haemodialysis, perform a desferrioxamine test and review the management of their condition accordingly. 2006 1. 10. 8 Consider specialist referral for people with erythropoiesis-stimulating agent-induced PRCA. 2006, amended NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 2011 Role of blood transfusion in managing erythropoiesis-stimulating agent resistance 1. 10. 9 Consider referring adults, children and young people with erythropoiesis-stimulating agent resistance to a haematology service, particularly if an underlying haematological disorder is suspected. 2015 1. 10. 10 Evaluate and discuss the risks and benefits of red cell transfusion with the person or, if appropriate, with their family or carers. 2015 1. 10. 11 Take into account the persons symptoms, quality of life, underlying conditions and the chance of a future successful kidney transplant, in addition to hemoglobin levels, when thinking about the need for red cell transfusion. 2015 1. 10. 12 Review the rate of red cell transfusion and consider a trial period of stopping erythropoiesis-stimulating agent in people who have erythropoiesis-stimulating agent resistance (typically on haemodialysis and on high-dose erythropoiesis-stimulating agent) and are having frequent transfusions when: all reversible causes of erythropoiesis-stimulating agent resistance have been taken into account and excluded and the persons condition is otherwise stable (without intercurrent illness such as infection) and the person is receiving adequate dialysis. Review the rate of red cell transfusion between 1 and 3 months after stopping erythropoiesis-stimulating agent therapy. If the rate of transfusion has increased, consider restarting erythropoiesis-stimulating agent therapy. 2015 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 11 Hyperphosphataemia in people with chronic kidney disease stage 4 or 5 Dietary management for adults, children and young people 1. 11. 1 A specialist renal dietitian, supported by healthcare professionals with the necessary skills and competencies, should carry out a dietary assessment and give individualised information and advice on dietary phosphate management. 2013 1. 11. 2 Tailor advice on dietary phosphate management to the persons learning needs and preferences, rather than using a generalised or complex multicomponent programme of delivery. 2013 1. 11.",
    "word_count": 568,
    "char_count": 3932,
    "sentence_count": 46,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 19,
      "total_chunks": 36,
      "position": "20/36",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "phosphate",
        "hemoglobin",
        "dietitian",
        "renal dietitian",
        "erythropoietin",
        "dialysis",
        "kidney transplant",
        "quality of life",
        "stage 4"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 20,
    "text": "2013 1. 11. 3 Give information about controlling intake of phosphate-rich foods (in particular, foods with a high phosphate content per gram of protein, as well as food and drinks with high levels of phosphate additives) to control serum phosphate, while avoiding malnutrition by maintaining a protein intake at or above the minimum recommended level. For people on dialysis, take into account possible dialysate protein losses. 2013 1. 11. 4 If a nutritional supplement is needed to maintain protein intake in children and young people with hyperphosphataemia, offer a supplement with a lower phosphate content, taking into account the persons preference and other nutritional requirements. 2013 Before starting phosphate binders for adults, children and young people 1. 11. 5 Before starting phosphate binders for adults, children and young people with chronic kidney disease stage 4 or 5, optimise: diet (see recommendations 1. 4. 7 to 1. 4. 9 for adults) dialysis, for people who are having this. 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 11. 6 When offering a phosphate binder, explain to them and their family members or carers (as appropriate): the reason for offering phosphate binders the risks if they are not taken the side effects linked to phosphate binders when and how they have to be taken (depending on the type of binder), including the exact timing (before, with or after food) and the need to take them with food containing phosphate (including, for example, high-protein snacks). 2021 1. 11. 7 Take into account the persons preferences on phosphate binders. 2021 1. 11. 8 If the person has problems taking the first phosphate binder offered, consider switching to the next recommended one (see recommendations 1. 11. 9 to 1. 11. 15). 2021 Phosphate binders for children and young people 1. 11. 9 Offer children and young people with chronic kidney disease stage 4 or 5 and hyperphosphataemia a calcium-based phosphate binder to control serum phosphate levels. 2021 In August 2021, this was an off-label use of some calcium-based phosphate binders in people not on dialysis. See NICEs information on prescribing medicines. 1. 11. 10 If serum calcium increases towards, or above, the age-adjusted upper normal limit: investigate possible causes other than the phosphate binder consider reducing the dose of the calcium-based phosphate binder and adding sevelamer carbonate or switching to sevelamer carbonate alone. 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) In August 2021, this was an off-label use of sevelamer carbonate. See NICEs information on prescribing medicines. 1. 11. 11 For all children and young people who are taking more than 1 phosphate binder, titrate the dosage to achieve the best possible control of serum phosphate while keeping serum calcium levels below the upper normal limit. 2021 Phosphate binders for adults First phosphate binder for adults 1. 11. 12 Offer adults with chronic kidney disease stage 4 or 5 and hyperphosphataemia calcium acetate to control serum phosphate levels. 2021 In August 2021, this was an off-label use of calcium acetate in people not on dialysis. See NICEs information on prescribing medicines. 1. 11. 13 Offer sevelamer carbonate if calcium acetate is not indicated (for example, because of hypercalcaemia or low serum parathyroid hormone levels) or not tolerated. 2021 In August 2021, this was an off-label use of sevelamer carbonate. See NICEs information on prescribing medicines. 1. 11.",
    "word_count": 579,
    "char_count": 3680,
    "sentence_count": 58,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 20,
      "total_chunks": 36,
      "position": "21/36",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "calcium",
        "phosphate",
        "parathyroid hormone",
        "diet",
        "phosphate binders",
        "malnutrition",
        "dialysis",
        "dialysate",
        "stage 4"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 21,
    "text": "2021 In August 2021, this was an off-label use of sevelamer carbonate. See NICEs information on prescribing medicines. 1. 11. 14 If calcium acetate and sevelamer carbonate cannot be used, consider: sucroferric oxyhydroxide, for adults on dialysis if a calcium-based phosphate binder is not needed or calcium carbonate, if a calcium-based phosphate binder is needed. In August 2021, this was an off-label use of these phosphate binders in people not on dialysis. See NICEs information on prescribing medicines. 2021 1. 11. 15 Only consider lanthanum carbonate for adults with chronic kidney disease stage 4 or 5 if other NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) phosphate binders cannot be used. In August 2021, this was an off-label use of lanthanum carbonate phosphate binders in people not on dialysis and with serum phosphate levels less than 1. 78 millimoles per liter. See NICEs information on prescribing medicines. 2021 Combinations of phosphate binders for adults 1. 11. 16 If adults with chronic kidney disease stage 4 or 5 remain hyperphosphataemic after taking the maximum dose recommended in the BNF (or the maximum dose they can tolerate if that is lower), of a calcium-based phosphate binder: check they are taking it as prescribed consider combining a calcium-based phosphate binder with a non-calciumbased phosphate binder. 2021 1. 11. 17 For all adults who are taking more than 1 phosphate binder, titrate the dosage to achieve the best possible control of serum phosphate while keeping serum calcium levels below the upper normal limit. 2021 Review of treatments in adults, children and young people 1. 11. 18 At every routine clinical review, assess the persons serum phosphate control, taking into account: diet whether they are taking the phosphate binders as prescribed other relevant factors, such as vitamin D levels, serum parathyroid hormone levels, alkaline phosphatase, serum calcium, medications that might affect serum phosphate, or dialysis. 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) For a short explanation of why the committee made these 2021 recommendations and how they might affect practice, see the rationale and impact section on hyperphosphataemia in people with chronic kidney disease stage 4 or 5. Full details of the evidence and the committees discussion are in evidence review L: use of phosphate binders. 1. 12 Other complications in adults Bone metabolism and osteoporosis 1. 12. 1 Do not routinely measure calcium, phosphate, parathyroid hormone and vitamin D levels in adults with a glomerular filtration rate of 30 milliliters per minute/1. 73 m2 or more (glomerular filtration rate category G1, G2 or G3). 2008 1. 12. 2 Measure serum calcium, phosphate and parathyroid hormone concentrations in adults with a glomerular filtration rate of less than 30 milliliters per minute/1. 73 m2 (glomerular filtration rate category G4 or G5). Determine the subsequent frequency of testing by the measured values and the clinical circumstances. If doubt exists, seek specialist opinion. 2008 1. 12. 3 Offer bisphosphonates if indicated for the prevention and treatment of osteoporosis in adults with a glomerular filtration rate of 30 milliliters per minute/1. 73 m2 or more (glomerular filtration rate category G1, G2 or G3). 2008 Vitamin D supplements in the management of chronic kidney diseasemineral and bone disorders Detailed advice on the management of chronic kidney diseasemineral and bone disorders is beyond the scope of this guideline. If uncertain, seek advice from your local renal service. 1. 12.",
    "word_count": 584,
    "char_count": 3760,
    "sentence_count": 49,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 21,
      "total_chunks": 36,
      "position": "22/36",
      "content_type": "treatment",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "calcium",
        "phosphate",
        "parathyroid hormone",
        "vitamin D",
        "diet",
        "phosphate binders",
        "supplements",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 22,
    "text": "If uncertain, seek advice from your local renal service. 1. 12. 4 Do not routinely offer vitamin D supplementation to manage or prevent chronic kidney diseasemineral and bone disorders. 2014 1. 12. 5 Offer colecalciferol or ergocalciferol to treat vitamin D deficiency in people with chronic kidney disease and vitamin D deficiency. 2014 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) 1. 12. 6 If vitamin D deficiency has been corrected and symptoms of chronic kidney diseasemineral and bone disorders persist, offer alfacalcidol (1-alpha-hydroxycholecalciferol) or calcitriol (1-25-dihydroxycholecalciferol) to people with a glomerular filtration rate of less than 30 ml/ min/1. 73 m2 (glomerular filtration rate category G4 or G5). 2014 1. 12. 7 Monitor serum calcium and phosphate concentrations in people receiving alfacalcidol or calcitriol supplements. 2014 Oral bicarbonate supplements in the management of metabolic acidosis Detailed advice on the management of metabolic acidosis is beyond the scope of this guideline. If uncertain, seek advice from your local renal service. 1. 12. 8 Consider oral sodium bicarbonate supplementation for adults with both: a glomerular filtration rate less than 30 milliliters per minute/1. 73 m2 (glomerular filtration rate category G4 or G5) and a serum bicarbonate concentration of less than 20 mmol/litre. 2014 Terms used in this guideline This section defines terms that have been used in a particular way for this guideline. For other definitions see the NICE glossary. Chronic kidney disease (chronic kidney disease) Abnormalities of kidney function or structure present for more than 3 months, with implications for health. This includes all people with markers of kidney damage and those with a glomerular filtration rate (glomerular filtration rate) of less than 60 milliliters per minute/1. 73 m2 on at least 2 occasions separated by a period of at least 90 days (with or without markers of kidney damage). Classification of chronic kidney disease chronic kidney disease is classified according to estimated glomerular filtration rate (estimated glomerular filtration rate) and albumin: creatinine ratio (albumin-creatinine ratio) NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) (see table 1), using G to denote the glomerular filtration rate category (G1 to G5, which have the same glomerular filtration rate thresholds as the chronic kidney disease stages 1 to 5 recommended previously) and A for the albumin-creatinine ratio category (A1 to A3), for example: A person with an estimated glomerular filtration rate of 25 milliliters per minute/1. 73 m2 and an albumin-creatinine ratio of 15 magnesium/mmol has chronic kidney disease G4A2. A person with an estimated glomerular filtration rate of 50 milliliters per minute/1. 73 m2 and an albumin-creatinine ratio of 35 magnesium/mmol has chronic kidney disease G3aA3. An estimated glomerular filtration rate of less than 15 milliliters per minute/1. 73 m2 (glomerular filtration rate category G5) is referred to as kidney failure. Glomerular filtration rate (glomerular filtration rate) This is abbreviated in the following way in this guideline: glomerular filtration rate: either a measured or an estimated glomerular filtration rate estimated glomerular filtration rate: estimated glomerular filtration rate (without indicating the method of estimation) eGFRcreatinine: an estimation of glomerular filtration rate using serum creatinine 4-variable Kidney Failure Risk Equation A persons 5-year risk of needing renal replacement therapy (defined as the need for dialysis or transplant) is estimated, as in Major 2019, as: In the above, estimated glomerular filtration rate is reported in milliliters per minute/1. 73 m2 and albumin-creatinine ratio in magnesium/mmol.",
    "word_count": 584,
    "char_count": 3974,
    "sentence_count": 39,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 22,
      "total_chunks": 36,
      "position": "23/36",
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "creatinine",
        "sodium",
        "calcium",
        "phosphate",
        "magnesium",
        "bicarbonate"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 23,
    "text": "73 m2 and albumin-creatinine ratio in magnesium/mmol. Where the term male is used, this should be replaced by a 1 if the person being assessed is male, and a 0 if they are female. This equation and its coefficients are validated in a UK population, and it is important to use this version, and not a version validated in another country. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Markers of kidney damage These include albuminuria (albumin-creatinine ratio more than 3 magnesium/mmol), urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, abnormalities detected by histology, structural abnormalities detected by imaging, and a history of kidney transplantation. Pre-dialysis Usually regarded to be chronic kidney disease stages 4 and 5, although there is no accepted definition. Predialysis includes people with a failing transplant and people having conservative management. Renal replacement therapy (RRT) Life-supporting treatments for severe acute kidney injury or stage 5 chronic kidney disease. This includes haemodialysis, haemofiltration, haemodiafiltration, peritoneal dialysis and kidney transplantation. Reninangiotensinaldosterone system antagonist A medicine that blocks or inhibits the reninangiotensinaldosterone system, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), direct renin inhibitors and aldosterone antagonists. Reninangiotensin system antagonist A medicine that blocks or inhibits the reninangiotensin system, including ACE inhibitors, ARBs and direct renin inhibitors. This group of medicines does not include aldosterone antagonists. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Recommendations for research As part of the 2021 update, the guideline committee made 18 recommendations for research on chronic kidney disease (chronic kidney disease). They prioritised 5 key recommendations for research. They also retained some recommendations for research from previous guidelines. Key recommendations for research 1 Creatinine-based estimate of estimated glomerular filtration rate existing calculations In adults, children and young people from black, Asian and other minority ethnic groups with chronic kidney disease living in the UK, which existing estimated glomerular filtration rate calculations are the most accurate? 2021 2 Creatinine-based estimate of estimated glomerular filtration rate improving accuracy of calculations In adults, children and young people from black, Asian and other minority ethnic groups with chronic kidney disease living in the UK, what biomarkers or factors, other than ethnicity, improve the diagnostic accuracy of estimated glomerular filtration rate calculations? 2021 For a short explanation of why the committee made this recommendation for research, see the rationale on creatinine-based estimate of glomerular filtration rate. Full details of the evidence and the committees discussion are in evidence review A: diagnostic accuracy of estimated glomerular filtration rate calculations in adults, children, and young people from black, Asian and other minority ethnic groups with chronic kidney disease. 3 Risk assessment for black, Asian and minority ethnic groups What is the accuracy of the 4-variable Kidney Failure Risk Equation in adults, children and young people with chronic kidney disease from black, Asian and minority ethnic groups living in the UK? 2021 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) For a short explanation of why the committee made this recommendation for research, see the rationale on risk assessment, referral criteria and shared care. Full details of the evidence and the committees discussion are in evidence review F: the best combination of measures to identify increased risk of progression in adults, children and young people.",
    "word_count": 574,
    "char_count": 4125,
    "sentence_count": 30,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 23,
      "total_chunks": 36,
      "position": "24/36",
      "content_type": "treatment",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "kidney failure",
        "albuminuria",
        "creatinine",
        "magnesium",
        "ACE inhibitors",
        "ARBs",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 24,
    "text": "4 Managing anaemia optimal hemoglobin levels for children and young people What is the efficacy and safety of different aspirational haemoglobin (hemoglobin) targets for children and young people with chronic kidney disease undergoing treatment for anaemia? 2021 For a short explanation of why the committee made this recommendation for research, see the rationale on optimal hemoglobin levels. Full details of the evidence and the committees discussion are in evidence review J: aspirational haemoglobin target range for children and young people with chronic kidney disease. 5 Hyperphosphatemia in people with chronic kidney disease stage 4 or 5 What are people with chronic kidney disease and their family members and carers views and beliefs about taking oral phosphate binders? 2021 For a short explanation of why the committee made this recommendation for research, see the rationale on hyperphosphataemia in people with chronic kidney disease stage 4 or 5. Full details of the evidence and the committees discussion are in evidence review L: use of phosphate binders. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Other recommendations for research 6 Cystatin-C equations What is the diagnostic accuracy of cystatin-C equations to estimate glomerular filtration rate as a measurement of kidney function in adults, young people and children in the UK? 2021 7 Investigations for proteinuria In children and young people, what is the accuracy of reagent strips for detecting albumin in urine? 2021 What is the effect of measuring proteinuria with albumin: creatinine ratio compared with protein: creatinine ratio on the timing of treatment changes in children and young people with chronic kidney disease? 2021 8 Frequency of monitoring For adults, children and young people with chronic kidney disease, what is the optimal monitoring frequency for albumin: creatinine ratio? 2021 9 Risk assessment, referral criteria and shared care What is the association between risk factors and chronic kidney disease outcomes in children and young people? 2021 What is the accuracy of the 4-variable Kidney Failure Risk Equation in children and young people living in the UK? 2021 10 Frequency of review What is the most clinical and cost-effective frequency of review for children and young people with chronic kidney disease? 2021 11 Managing anaemia For adults, children and young people with chronic kidney disease and anaemia, what is the diagnostic NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) accuracy of estimated glomerular filtration rate thresholds of 60, 45, and 30 milliliters per minute/1. 73 m2 for determining whether the anaemia is due to chronic kidney disease? 2021 For adults, children and young people with chronic kidney disease and anaemia who are on peritoneal dialysis, what amount of intravenous (IV) iron is most clinically and cost effective in managing anaemia and its associated outcomes (including quality of life)? 2021 What are the long-term consequences of high ferritin levels (above 800 micrograms/litre) in children and young people with chronic kidney disease? 2021 12 Phosphate binders Which binders are the most clinically and cost effective in controlling serum phosphate in adults, children and young people with stage 4 or 5 chronic kidney disease who are not on dialysis? 2021 In adults with stage 4 or 5 chronic kidney disease, including those on dialysis, what is the clinical and cost effectiveness and safety of long-term calcium acetate combined with magnesium carbonate for controlling serum phosphate?",
    "word_count": 572,
    "char_count": 3742,
    "sentence_count": 25,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 24,
      "total_chunks": 36,
      "position": "25/36",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "proteinuria",
        "creatinine",
        "calcium",
        "phosphate",
        "magnesium",
        "hemoglobin"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 25,
    "text": "2021 13 Self-management of chronic kidney disease Does the provision of educational and supportive interventions to people with chronic kidney disease by healthcare professionals increase the persons skills and confidence in managing their conditions and improve clinical outcomes? 2014 14 Antiplatelet therapy For people with chronic kidney disease at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease? 2014 15 Reninangiotensinaldosterone system antagonists For people aged over 75 years with chronic kidney disease, what is the clinical effectiveness of reninangiotensinaldosterone system (RAAS) antagonists? 2014 16 Vitamin D supplements in the management of chronic kidney diseasemineral NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) and bone disorders In people with hyperparathyroidism secondary to chronic kidney disease, does treatment with vitamin D or vitamin D analogues improve patient-related outcomes? 2014 17 Management of anaemia of chronic kidney disease with concurrent illness What is the optimal management (in terms of clinical and cost effectiveness) of anaemia of chronic kidney disease in people who are receiving erythropoietic stimulating agents (ESAs) and have a significant concurrent acute infectious illness? 2015 18 Treatment of erythropoiesis-stimulating agent resistance in people on haemodialysis What is the most effective type of intervention to treat people on haemodialysis with erythropoiesis-stimulating agent-resistant anaemia? 2015 NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Rationale and impact These sections briefly explain why the committee made the recommendations and how they might affect practice. Creatinine-based estimate of glomerular filtration rate (glomerular filtration rate) Why the committee did not make recommendations Evidence on the specific estimated glomerular filtration rate equations or ethnicity adjustments seen by the committee was not from UK studies so may not be applicable to UK black, Asian and minority ethnic groups. None of the studies included children and young people. The committee was also concerned about the value of P30 as a measure of accuracy (P30 is the probability that the measured value is within 30% of the true value), the broad range of P30 values found across equations and the relative value or accuracy of ethnicity adjustments to estimated glomerular filtration rate equations in different ethnic groups. The committee agreed that adding an ethnicity adjustment to estimated glomerular filtration rate equations for different ethnicities may not be valid or accurate. Categorisations based on ethnicity lump together people with a diverse range of family backgrounds and differences in estimated glomerular filtration rate across ethnicities are likely to at least partly arise because of differences in average muscle mass between ethnic groups. However, muscle mass also differs from person to person within the same ethnicity and so making an adjustment based on ethnicity may be inaccurate for some people. Therefore, the committee agreed to remove the 2014 recommendation on how to adjust the chronic kidney disease-EPI creatinine equation for adults of African-Caribbean or African family origin. The committee highlighted the 2008 recommendation, which states that caution should be used when interpreting estimated glomerular filtration rate and in adults with extremes of muscle mass and on those who consume protein supplements (this was added to recommendation 1. 1. 1). The committee made recommendations for research on appropriate estimated glomerular filtration rate equations for black, Asian and minority ethnic groups (adults, children and young people) in the UK. They agreed that factors other than ethnicity should also be explored as biomarkers.",
    "word_count": 585,
    "char_count": 4094,
    "sentence_count": 25,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 25,
      "total_chunks": 36,
      "position": "26/36",
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "creatinine",
        "vitamin D",
        "supplements",
        "cardiovascular disease"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 26,
    "text": "They agreed that factors other than ethnicity should also be explored as biomarkers. The committee agreed that in the absence of good evidence for their accuracy, the 2014 recommendations that cystatin-c equations should be considered during diagnosis in certain circumstances, should be removed. In particular, they noted that although using NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) cystatin-c equations may reduce false-positive results, it is likely to also increase falsenegative results. This will avoid potentially misleading tests being conducted and the costs associated with these. They made a recommendation for research for a large study using UK data to evaluate the accuracy of cystatin-c equations. Impact on practice There will be an impact on practice, as the adjustment of the chronic kidney disease-EPI creatinine equation for adults of African-Caribbean or African family origin has been removed from the guideline. Only a small number of centres in the UK currently use cystatin-c equations regularly, so most should not be affected by the removal of the cystatin-c recommendations. Return to recommendations Investigations for proteinuria Recommendations 1. 1. 10 to 1. 1. 14 Why the committee made the recommendations For children and young people with chronic kidney disease, there was no evidence for the accuracy of measuring albumin: creatinine ratio (albumin-creatinine ratio) compared with protein: creatinine ratio (protein-creatinine ratio) to quantify proteinuria. The committee discussed the recommendations for adults and agreed that, overall, these fit well with current practice and can be recommended for children and young people as well. The committee discussed the estimated glomerular filtration rate threshold recommended for quantifying urinary albumin or urinary protein loss in adults without diabetes. They agreed that this threshold is not appropriate for children and young people because any reduction in glomerular filtration rate in this population would prompt measuring proteinuria. Therefore, for children and young people they set the threshold for creatinine as above the upper limit of the age-appropriate reference range. The committee agreed to make a recommendation for research to identify the effect of measuring proteinuria with albumin-creatinine ratio compared with protein-creatinine ratio on the timing of treatment changes in children and young people with chronic kidney disease and the consequences of the delay in treatment NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) changes on different levels of proteinuria. How the recommendations might affect practice The recommendations are in line with current practice, so no additional resources should be needed. Return to recommendations Reagent strips for proteinuria and haematuria Recommendations 1. 1. 15 to 1. 1. 16 Why the committee made the recommendations The evidence showed that reagent strips were less useful to rule out than to rule in proteinuria. The committee highlighted that ruling out proteinuria with confidence was the main goal when using reagent strips. Therefore, they agreed that reagent strips should not be used to identify proteinuria in children and young people. The evidence was not reviewed for adults and so the committee agreed to retain the 2014 recommendation not to use reagent strips to identify proteinuria in adults unless the strips are capable of specifically measuring albumin at low concentrations and expressing the result as an albumin-creatinine ratio. The committee also highlighted that these tests are commonly used in clinical practice and agreed to make a further recommendation for further investigations in adults, children and young people with an incidental finding of unexplained proteinuria on reagent strips.",
    "word_count": 585,
    "char_count": 3986,
    "sentence_count": 33,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 26,
      "total_chunks": 36,
      "position": "27/36",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "proteinuria",
        "creatinine",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 27,
    "text": "Further testing is needed to confirm chronic kidney disease by identifying other markers of kidney damage (such as albumin-creatinine ratio or glomerular filtration rate). There was limited evidence on the accuracy of reagent strips for albuminuria, so the committee did not feel able to make recommendations. There were only 2 studies, and only 1 showed that reagent strips could be useful. There was no evidence on the accuracy of reagent strips for haematuria in children and young people. The 2014 guideline (which did not cover children and young people) recommended reagent strips for detecting haematuria in adults. The committee agreed to extend this recommendation to children and young people, because the evidence for adults is likely to be applicable to this population. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) How the recommendations might affect practice The recommendations are in line with current practice, so no additional resources should be needed. The committee noted that if all dipstick tests are confirmed by laboratory testing anyway, there would be extra costs attached to using dipsticks as a first step, which were not justified by the benefits. Return to recommendations Who should be tested for chronic kidney disease Recommendations 1. 1. 20 to 1. 1. 25 Why the committee made the recommendations For children and young people, the evidence showed that acute kidney injury and solitary functioning kidney were clinically significant risk factors for developing chronic kidney disease. The committee highlighted that solitary functioning kidney was not due to kidney donation but to nephrectomy secondary to congenital anomalies of the kidney and urinary tract or to a lack of a kidney at birth or a non-functioning kidney. The committee highlighted that there were other important risk factors for developing chronic kidney disease in children and young people, but that no evidence was found for these. Based on their clinical knowledge and experience, they added gout as a risk factor for adults and low birth weight as a risk factor for children and young people. The committee agreed that the frequency of monitoring (for developing chronic kidney disease or progression) should be individualised for adults, children and young people. This is to address the different characteristics and risks that each person will have. The committee agreed that more research on risk factors for developing chronic kidney disease in children and young people would help to strengthen current guidance, so they made a recommendation for research. How the recommendations might affect practice The recommendations are in line with current practice, so no additional resources should be needed. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Return to recommendations Frequency of monitoring Recommendations 1. 3. 1 to 1. 3. 4 Why the committee made the recommendations Most of the evidence showed that with estimated glomerular filtration rate decline, the risk of kidney disease progression and mortality increases, and this risk increases with the rate of estimated glomerular filtration rate decline. The committee agreed this is observed in clinical practice and any person presenting with an increase in estimated glomerular filtration rate decline would be monitored more frequently. The committee reviewed the recommendations and agreed that they are consistent with the evidence and clinical practice. They agreed to clarify monitoring by stating that repeat assessment is to be agreed with each person with or at risk of chronic kidney disease.",
    "word_count": 578,
    "char_count": 3782,
    "sentence_count": 34,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 27,
      "total_chunks": 36,
      "position": "28/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "glomerular filtration rate",
        "albuminuria",
        "creatinine",
        "monitoring",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 28,
    "text": "The committee agreed that the frequency of monitoring they recommended was a minimum level and that more frequent monitoring would be appropriate for some patients. This should also be guided by rate of change in estimated glomerular filtration rate or albumin-creatinine ratio and specific comorbidities, including diabetes. albumin-creatinine ratio monitoring should be individualised. For example, albumin-creatinine ratio might be monitored more frequently in people with high albumin-creatinine ratio (categories A2 or A3), or if a change in albumin-creatinine ratio would affect management. The committee made a recommendation for research to identify the optimal frequency of albumin-creatinine ratio monitoring in adults, children and young people with chronic kidney disease. The committee discussed whether specific recommendations are needed for children and young people with chronic kidney disease and decline in estimated glomerular filtration rate, but agreed that this population would be referred to specialist care. How the recommendations might affect practice The committee noted that no changes had been made to the previous suggested monitoring schedule, and they believed it was relatively well implemented in clinical practice. Therefore, they were confident there should not be a substantial impact on practice from the new recommendations. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) Return to recommendations Risk assessment, referral criteria and shared care Recommendation 1. 5. 1 to 1. 5. 9 Why the committee made the recommendations New evidence found a UK validation of the 4-variable Kidney Failure Risk Equation for adults, which can be used as one of the referral criteria (5-year risk of needing renal replacement therapy greater than 5%). The results of both the validation study and costeffectiveness modelling undertaken for the guideline showed using this equation and threshold as a referral criteria (rather than an estimated glomerular filtration rate threshold) was likely to be both more sensitive and more specific than the criteria in the 2014 NICE guideline, meaning people who will progress to needing renal replacement therapy are identified earlier, and there are fewer unnecessary referrals to secondary care. The benefits of this approach over using an estimated glomerular filtration rate threshold (as in the 2014 NICE guideline) were not large, but the committee agreed they were meaningful. They also agreed there were additional potential benefits of using the 4-variable Kidney Failure Risk Equation, including the ability to provide people with an individual risk assessment, which could help them to proactively manage their own risk, and inform the management plans in secondary care. However, validation of the risk equation was only in adults, so the committee made a separate recommendation for children and young people. Black people were underrepresented in the study and, although there was a sizeable proportion of people of Asian family origin, the location of the study suggests that people of east Asian family origin were likely to be under-represented. Therefore, the committee agreed to make a recommendation for research for validation of the risk equation. The committee agreed that it is important to discuss with a person with chronic kidney disease what risk means. They added additional recommendations on providing information about risk, using jargon-free language, allowing enough time for discussions and documenting any decisions made. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) How the recommendations might affect practice If the 4-variable Kidney Failure Risk Equation can be built into laboratory computer systems, as part of how estimated glomerular filtration rate and albumin-creatinine ratio results are returned to GPs, there should be no difficulty in implementing the recommendations.",
    "word_count": 599,
    "char_count": 4082,
    "sentence_count": 28,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 28,
      "total_chunks": 36,
      "position": "29/36",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "creatinine",
        "monitoring",
        "guideline",
        "albumin-creatinine ratio"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 29,
    "text": "Because the calculation requires both an estimated glomerular filtration rate and albumin-creatinine ratio value, it can only be produced if the GP requests both those measurements. These recommendations are intended to provide additional information to supplement estimated glomerular filtration rate and albumin-creatinine ratio values, rather than changing how often these values are requested by GPs. There may be particular difficulties for laboratories that store estimated glomerular filtration rate and albumin-creatinine ratio values on separate systems that cannot automatically communicate. In this situation, calculations may have to be done manually. However, this is still likely to be a more efficient system than calculations being carried out routinely by GPs. Overall, the referral criteria are predicted to slightly reduce monitoring costs but, excluding costs associated with dialysis, overall there should be no substantial impact on resource use. There may be an implementation period before the risk equation results are available to all GPs. Until then, some GPs may have to continue to base referral decisions on estimated glomerular filtration rate and albumin-creatinine ratio values independently, as is currently done, without providing patients with a quantitative assessment of their risk of needing renal replacement therapy. The faster these recommendations can be routinely adopted the less time it will be necessary for these 2 parallel approaches to both be in use. Return to recommendations Pharmacotherapy for blood pressure control Recommendations 1. 6. 1 to 1. 6. 3 Why the committee made the recommendations Results from a meta-analysis (including the SPRINT trial) showed no meaningful difference between standard and more intensive blood pressure targets for adults with chronic kidney disease. The 2014 guideline recommended maintaining systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg. This is consistent with clinical practice and with the NICE guideline on managing hypertension for people aged under 80. The committee noted that although there is limited evidence on blood pressure targets in people with chronic kidney disease NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) and proteinuria, it is important to maintain a systolic blood pressure below 130 mmHg and a diastolic pressure below 80 mmHg. The committee agreed that none of the evidence they had seen warranted changing the recommendations. They also noted that intensive blood pressure targets only result in a marginal reduction in stroke and kidney failure, but put a large burden on patients in terms of polypharmacy and associated risks and side effects (such as falls). The committee agreed that a useful target for blood pressure in children and young people with chronic kidney disease and proteinuria is a systolic blood pressure below the 50th percentile for height. The committee agreed that particular care had to be taken with people who were frail or who had multiple morbidities. However, the NICE guideline on hypertension already covers this group, so the committee did not make new recommendations. How the recommendations might affect practice The recommendations for adults are consistent with current practice and should not have an impact on resources. The recommendation for blood pressure targets in children and young people may have some cost implications, although the committee did not think they would be significant. Return to recommendations Pharmacotherapy for proteinuria and choice of antihypertensive agent Recommendations 1. 6. 5 to 1. 6. 12 Why the committee made the recommendations The interventions recommended are intended to improve a range of outcomes, including rates of progression to end-stage renal disease. There was evidence for adults, but not for children and young people.",
    "word_count": 591,
    "char_count": 3963,
    "sentence_count": 33,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 29,
      "total_chunks": 36,
      "position": "30/36",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "end-stage renal disease",
        "proteinuria",
        "creatinine",
        "antihypertensive",
        "dialysis",
        "blood pressure control",
        "monitoring"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 30,
    "text": "There was evidence for adults, but not for children and young people. Paediatric experts on the committee agreed that the evidence for adults was also applicable to children and young people. Therefore, the committee did not make separate recommendations for different age groups. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) The evidence for adults covered people with proteinuria or albuminuria, and included people with diabetes. This allowed the committee to make separate recommendations for people with and without diabetes. In the committees experience, many people with diabetes and chronic kidney disease are frail, or are taking a lot of medicines, so they made a recommendation to address this. People without diabetes The evidence showed that, compared with placebo, ACE inhibitors reduced the risk of end-stage renal disease in people without diabetes. ARBs did not show the same effect. However, the committee did not believe the evidence was sufficiently robust to show that ACE inhibitors were better than ARBs. In addition, for people with type 2 diabetes, ARBs did reduce the risk of end-stage renal disease and heart failure. Based on the limitations of the evidence and the evidence available for people with type 2 diabetes, the committee recommended both ACE inhibitors and ARBs. People with type 2 diabetes For people with type 2 diabetes, ARBs reduced the risk of end-stage renal disease and heart failure. The committee also recommended ACE inhibitors because the evidence did not show a clear difference between ACE inhibitors and ARBs on the following outcomes: reduction of proteinuria end-stage renal disease all-cause mortality cardiovascular mortality non-fatal cardiovascular events adverse events (hypotension) hospitalisation. There was no evidence comparing ACE inhibitors with placebo in people with type 2 diabetes. The evidence for people without diabetes did show that ACE inhibitors reduced the risk of end-stage renal disease, compared with placebo. The committee used this evidence to make the recommendation for people with diabetes. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) How the recommendations might affect practice The recommendations reflect current practice, so no additional resources should be needed. Return to recommendations Diagnostic role of glomerular filtration rate Recommendation 1. 7. 2 Why the committee made the recommendation There was limited evidence showing that estimated glomerular filtration rate thresholds below 60 milliliters per minute/1. 73 m2 could be used to identify anaemia as being due to chronic kidney disease. The committee questioned the applicability of this evidence because the studies did not rule out other causes of anaemia (which is usually done in practice). The limited evidence meant that the committee was unable to recommend specific thresholds or probabilities. Instead, they used the available evidence and their expertise to specify ranges of glomerular filtration rate indicating that anaemia is more or less likely to be caused by chronic kidney disease. When anaemia may have other causes (such as gastrointestinal bleeding and certain cancers), investigating further will increase the chance of the real cause being identified and treated. Clinical judgement is needed on how extensively to look for other causes when estimated glomerular filtration rate is between 30 and 60 milliliters per minute/1. 73 m2. Healthcare professionals will need to balance the risks of: putting people through extensive and unnecessary investigations when their anaemia is caused by chronic kidney disease missing the real cause of their anaemia by assuming it is caused by chronic kidney disease. The committee agreed that when estimated glomerular filtration rate is below 30 milliliters per minute/1.",
    "word_count": 597,
    "char_count": 4000,
    "sentence_count": 35,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 30,
      "total_chunks": 36,
      "position": "31/36",
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "ACE inhibitors",
        "ARBs",
        "heart failure"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 31,
    "text": "The committee agreed that when estimated glomerular filtration rate is below 30 milliliters per minute/1. 73 m2, anaemia is more likely to be caused by chronic kidney disease. However, healthcare professionals should still use their clinical judgement and think about peoples circumstances when deciding whether further NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) assessment is needed. Only 1 study included people with diabetes, and no studies included children and young people. However, the recommendations still apply to these populations, because other causes of anaemia would be ruled out before attributing the anaemia to chronic kidney disease. The committee noted a need for further research on the diagnostic test accuracy of different estimated glomerular filtration rate thresholds, particularly for estimated glomerular filtration rate thresholds of 30 and 60 milliliters per minute/1. 73 m2. They highlighted that in clinical practice, an estimated glomerular filtration rate threshold of 45 milliliters per minute/1. 73 m2 can also trigger investigation into anaemia due to chronic kidney disease, but limited evidence was identified for the diagnostic accuracy of this threshold. The committee made a recommendation for research on the diagnostic accuracy of these specific estimated glomerular filtration rate thresholds for determining the likelihood of anaemia being chronic kidney disease related. How the recommendations might affect practice These recommendations should not increase the cost to primary care, because they reflect current practice and act as cautions for healthcare professionals to explore the cause of anaemia. They may reduce costs by ensuring that the correct cause of anaemia is identified more quickly with appropriate investigations. Return to recommendations Optimal hemoglobin levels Recommendation 1. 9. 11 Why the committee made the recommendation In the 2015 guideline, an aspirational hemoglobin range between 100 and 120 g/litre was recommended for adults, young people and children aged 2 years and over. For children under 2 years, the hemoglobin range was between 95 and 115 g/litre. These were based on evidence for adults. In 2020, the committee reviewed the evidence specifically for children and young people. The only evidence for this population came from a single small lowquality study, comparing the effects of a high and low hemoglobin target on left ventricular mass index. No difference in effect was found. Given the lack of evidence, the committee agreed that the recommendations made in 2015 should not be changed. NICE 2025. All rights reserved. Subject to Notice of rights (notice-of-rights). of 78 Chronic kidney disease: assessment and management (NG203) The 2015 guideline recommended using the same target hemoglobin range as adults for children and young people over 2 years, and a slightly lower level in children under 2. However, children and young people have different coagulation risks than adults, and are more prone to reductions in hemoglobin from blood loss in haemodialysis circuits. In practice, higher hemoglobin targets (up to 130 g/litre) are often used for children and young people. Because of the lack of evidence in this age group, the committee made a recommendation for research on optimal hemoglobin levels for managing anaemia in children and young people to inform future guidance Return to recommendations Correcting iron deficiency Recommendation 1. 9. 18 Why the committee made the recommendation For people with stage 5 chronic kidney disease who are on in-centre haemodialysis, the evidence showed that high-dose intravenous iron was better than a low-dose regimen at increasing levels of serum ferritin and haemoglobin as well as increasing the haematocrit.",
    "word_count": 578,
    "char_count": 3865,
    "sentence_count": 33,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 31,
      "total_chunks": 36,
      "position": "32/36",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "hemoglobin",
        "iron",
        "ferritin",
        "stage 5",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 32,
    "text": "The committee agreed that the type of intravenous iron was not relevant and that there was no reason to recommend a specific preparation. They also highlighted that there are differences between iron preparations that affect their bioequivalence. Therefore, pharmacist advice is likely to be needed when choosing iron preparations. An example regimen for adults using iron sucrose was taken from the evidence to help guide practice. Ultimately, the choice of preparation should be based on local availability and policies. The committee agreed that children and young people should be given a high dose as set out in the BNFc, although they noted that use of intravenous iron preparations in children under 14 years was off label. The committee was aware of a MHRA alert on intravenous iron and serious hypersensitivity reactions. The alert states that intravenous iron products should only be administered when staff trained to evaluate and manage anaphylactic or anaphylactoid reactions as well as resuscitation facilities are immediately available. The committee agreed that intravenous iron should not be administered at home but recognised that this has a significant impact on people on home dialysis. Most of the evidence was from studies with participants on haemodialysis. The committee NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) agreed that more research would help to inform future guidance on intravenous iron for people with stage 5 chronic kidney disease who are on peritoneal dialysis. How the recommendations might affect practice The recommendations are unlikely to lead to a substantial change in costs, as intravenous iron is relatively inexpensive, and there was evidence found in adults that use of high-dose iron leads to lower doses of erythropoiesis-stimulating agents being used, thereby offsetting any extra costs. Return to recommendations Hyperphosphataemia in people with chronic kidney disease stage 4 or 5 Recommendations 1. 11. 5 to 1. 11. 18 Why the committee made the recommendations There was a significant amount of evidence (of varying quality) for adults with stage 5 chronic kidney disease who are having dialysis. However, evidence was limited for adults not on dialysis, and for children and young people. The committee agreed to extrapolate from the evidence for adults with stage 5 chronic kidney disease on dialysis, so they could make recommendations for the other groups. Peoples preferences need to be taken into account when offering phosphate binders, because this could have an impact on adherence. The differences in phosphate binder formulations (for example, chewable and non-chewable) and the effect this has on how they are taken (before, with or after food) mean that people will often prefer one phosphate binder over the others. Oral phosphate binders are also unpleasant to take, and this might affect adherence as well. It is important to involve people in the choice of phosphate binder as far as possible, to ensure they are prescribed one they are happy with and can take as recommended. The committee highlighted several factors that renal physicians assess at clinical reviews for people who are taking phosphate binders (including parathyroid hormone, vitamin D and serum calcium). NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Which phosphate binders to use for children and young people The committee reviewed the recommendations from the 2013 guideline in the light of limited new evidence. For children and young people with high serum calcium, they agreed to recommend sevelamer carbonate instead of sevelamer hydrochloride. This is because sevelamer carbonate offers a better balance of benefits and costs.",
    "word_count": 596,
    "char_count": 3893,
    "sentence_count": 33,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 32,
      "total_chunks": 36,
      "position": "33/36",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "calcium",
        "phosphate",
        "parathyroid hormone",
        "vitamin D",
        "iron",
        "phosphate binders",
        "dialysis",
        "peritoneal dialysis",
        "adherence"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 33,
    "text": "This is because sevelamer carbonate offers a better balance of benefits and costs. The committee highlighted that in growing children and young people, calcium is often maintained close to, but not above the upper limit of the age-related reference range. Calcium is essential for bone development in children. Which phosphate binders to use for adults The committee reviewed the evidence for phosphate binders both in adults on dialysis and adults not having dialysis. Although the evidence for those not on dialysis was limited, it did reflect the evidence for adults on dialysis in every area apart from sucroferric oxyhydroxide. As there was no evidence on sucroferric oxyhydroxide in adults not on dialysis, the committee did not recommend it for this group. The evidence showed that the most cost-effective treatment strategy is to start with calcium acetate, and switch to sevelamer carbonate if the person gets hypercalcaemia. This is because: calcium acetate as a first-line treatment provides the best balance of benefits, harms and costs calcium carbonate is cheaper than calcium acetate, but is more likely to cause high serum calcium levels and associated adverse outcomes sevelamer carbonate and sevelamer hydrochloride are more expensive than calcium acetate, and do not provide enough benefit as a first-line treatment to justify the extra expense when people have high serum calcium levels and cannot take calcium acetate, sevelamer carbonate is the best alternative; it is cheaper than sevelamer hydrochloride, and provides similar benefits, however, it still costs more than calcium acetate and, for first-line treatment, it does not provide enough benefit to justify this extra expense sucroferric oxyhydroxide is not cost effective as a first-line treatment, but is a reasonable choice for people who cannot take calcium acetate or sevelamer NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) carbonate lanthanum carbonate is much more expensive than calcium acetate and sevelamer carbonate and may provide less benefit than other non-calcium-based phosphate binders. Based on this evidence, the committee recommended a treatment sequence and alternatives for different situations. The committee also agreed that diet and dialysis (when appropriate) had a large impact on serum phosphate levels. Therefore, before offering phosphate binders it is important to provide dietary advice and ensure people are on the dialysis regime that works best for them. The committee made a recommendation for research to address the lack of evidence in adults not on dialysis. How the recommendations might affect practice Replacing sevelamer hydrochloride with sevelamer carbonate may result in lower resource use, because there is a cheap generic version of sevelamer carbonate available. There is currently variation across the UK in use of sucroferric oxyhydroxide. The recommendation on this phosphate binder may increase costs. However, this increase is unlikely to be substantial, because sucroferric oxyhydroxide is only recommended as a third-line option. Return to recommendations NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Context Chronic kidney disease (chronic kidney disease) describes abnormal kidney function or structure. It is common and often occurs with other conditions (such as cardiovascular disease and diabetes). Moderate to severe chronic kidney disease is also associated with an increased risk of acute kidney injury, falls, frailty and mortality. The risk of developing chronic kidney disease increases with age. chronic kidney disease is usually asymptomatic, but it is detectable, and tests for chronic kidney disease are simple and available.",
    "word_count": 575,
    "char_count": 3890,
    "sentence_count": 27,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 33,
      "total_chunks": 36,
      "position": "34/36",
      "content_type": "reference",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "acute kidney injury",
        "kidney function",
        "calcium",
        "phosphate",
        "diet",
        "phosphate binders",
        "dialysis",
        "cardiovascular disease"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 34,
    "text": "chronic kidney disease is usually asymptomatic, but it is detectable, and tests for chronic kidney disease are simple and available. There is evidence that treatment can prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease. However, chronic kidney disease is often unrecognised or diagnosed at an advanced stage. Late presentation of people with kidney failure increases morbidity, mortality and associated healthcare costs. As kidney disease progresses, some coexisting conditions become more common and increase in severity. Hyperphosphataemia is an example of this, occurring because of insufficient filtering of phosphate from the blood by poorly functioning kidneys. This means that a certain amount of the phosphate does not leave the body in the urine, instead remaining in the blood at abnormally high levels. High serum phosphate levels can directly and indirectly increase parathyroid hormone secretion, leading to the development of secondary hyperparathyroidism. Left untreated, secondary hyperparathyroidism increases morbidity and mortality and may lead to renal bone disease, with people experiencing bone and muscular pain, fracture, bone and joint abnormalities, and vascular and soft tissue calcification. Many people with chronic kidney disease or established renal failure also develop associated anaemia. The prevalence of anaemia associated with chronic kidney disease increases progressively with the stage of chronic kidney disease, especially when the person reaches stage 4 or 5. Anaemia of chronic kidney disease contributes significantly to the burden of chronic kidney disease. However, it is potentially reversible and manageable with appropriate identification and treatment. The Health Survey for England (2016) found that 13% of adults (16 years and over) had any chronic kidney disease (stages 1 to 5). The prevalence of stages 3 to 5 was 5% for all adults, rising to 34% in people aged 75 and over. At the end of 2018 there were 826 children and young people and 66, 612 adults receiving renal replacement therapy in the UK according to the UK Renal Registry annual report. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Since publication of the previous guidelines, new evidence was identified for several areas. The following areas of the guideline have been updated: investigations for chronic kidney disease classification of chronic kidney disease frequency of monitoring for chronic kidney disease blood pressure control for people with chronic kidney disease phosphate binders to manage mineral and bone disorder in chronic kidney disease glomerular filtration rate for diagnosing anaemia associated with chronic kidney disease intravenous iron for treating anaemia associated with chronic kidney disease. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Finding more information and committee details To find NICE guidance on related topics, including guidance in development, see the NICE topic page on chronic kidney disease. For full details of the evidence and the guideline committees discussions, see the evidence reviews. You can also find information about how the guideline was developed, including details of the committee. NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see resources to help you put NICE guidance into practice. NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights).",
    "word_count": 556,
    "char_count": 3792,
    "sentence_count": 32,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 34,
      "total_chunks": 36,
      "position": "35/36",
      "content_type": "evidence",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal failure",
        "kidney failure",
        "phosphate",
        "parathyroid hormone",
        "iron",
        "phosphate binders",
        "bone disease",
        "cardiovascular disease"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 35,
    "text": "NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) Update information November 2021: We reviewed the evidence on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease and made new recommendations, which are in the section on chronic kidney disease in the NICE guideline on type 2 diabetes in adults. We also clarified the use of the term male in the 4-variable Kidney Failure Risk Equation. August 2021: This guideline is an update of NICE guideline CG182 (published July 2014), NICE guideline CG157 (published March 2013) and NICE guideline NG8 (published June 2015) and will replace them. We have reviewed the evidence and made new recommendations on the assessment and management of chronic kidney disease, management of hyperphosphataemia in people with chronic kidney disease and the management of anaemia for people with chronic kidney disease. These recommendations are marked 2021. We have also made some changes without an evidence review: We have updated some wording to bring the language and style up to date, without changing the meaning. We have updated some recommendations to bring them in line with current terminology and practice. We have combined, clarified or reworded some recommendations to make them clearer and to improve ease of reading. In recommendations ending 2006, 2006, amended 2011, 2006, amended 2015, 2008, 2008, amended 2014, or 2014, we have not reviewed the evidence. In some cases minor changes have been made for example, to update links, or bring the language and style up to date without changing the intent of the recommendation. Minor changes after publication August 2025: We added links to relevant technology appraisal guidance in the sections on pharmacotherapy and managing anaemia. September 2024: We added links to relevant technology appraisal guidance in the NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78 Chronic kidney disease: assessment and management (NG203) sections on pharmacotherapy and managing anaemia. November 2023: We added a link to NICEs guideline on hypertension to recommendation 1. 6. 4. ISBN: 978-1-4731-4233-6 NICE 2025. All rights reserved. Subject to Notice of rights ( conditionsnotice-of-rights). 78",
    "word_count": 357,
    "char_count": 2347,
    "sentence_count": 25,
    "metadata": {
      "source_file": "chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf",
      "extraction_date": "2025-11-21T14:29:29.632607",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "proteinuria"
      ],
      "chunk_index": 35,
      "total_chunks": 36,
      "position": "36/36",
      "content_type": "recommendation",
      "content_type_confidence": 2,
      "medical_entities": [
        "chronic kidney disease",
        "kidney failure",
        "guideline"
      ],
      "entity_count": 3
    }
  }
]